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Abstract. 
Effect of glutamate and adenosine A?a receptor agonists and antagonists on 
neuronal cell cultures.
"I
;#
In vivo data have shown that both adenosine Â2 a receptor agonists and antagonists are 
protective against neuronal damage produced by ischaemia. This project aimed to 
elucidate the direct role of the A%A receptor in neuronal viability using cortical 
neuronal cultures so that specific experimental questions in the whole animal can be 
formulated.
Cell death was assessed by trypan blue uptake. In cortical neuronal cultures, N- 
methyl-D-aspaitate ((NMDA) 0, 10, 30 & 100 JiM)) induced concentration-dependent 
cell death. This was attenuated by the NMDA selective antagonist, DL-2-amino-5- 
phosphonopentanoic acid (AP5) to control levels (p<0.01, n=13).
0.02 |liM  2-p-(2-carboxyethy)phenethylamino-5’-N-ethylcarboxamidoadenosine (CGS 
21680) reduced the level of cell death induced by 10 |aM and 30 |iM NMDA to below 
basal (control) levels. 0.05 jiM CGS 21680 showed a tendency to increase neuronal 
death. However, as the concentration of the compound was increased to 0.5 |aM and 
then 5 fxM there was a trend of decreased cell death. This was to the extent that at 5 
tiM, CGS 21680 reduced cell death induced by 30 |liM  NMDA to control levels.
0.05 p-M and 5 |aM 4-(2-[7-amino~2-{2-furyl}{ 1,2,4} triazolo {2,3-a}{ 1,3,5}triazin- 
5-yl-amino]ethyl) phenol (ZM 241385) reduced cell death induced by 100 pM 
NMDA to near control levels (p<0.01, n=4).
Quinolinic acid (300, 1000 & 3000 pM) induced a trend of increasing cell death in 
cortical neuronal cultures, an action which kynurenic acid (1000 pM) had no effect 
on.
In hippocampal neuronal cultures, N-methyl-D-aspartate (NMDA) also induced 
concentration-dependent cell death as assessed by trypan blue uptake. However, as 
assessed by (3-(4,5-dimethylthiazol-2-yl)-5-(-3-carboxymethoxyphenyl)-2-(-4- 
sulfophenyl)-2H-tetrazolium salt; (MTS) reduction, ImM NMDA caused an increase 
in neuronal viability (p<0.001, n=4) due to superoxide accumulation.
The data suggest that the adenosine AaA receptor activation is neuroprotective when 
cell damage is mild. However, activation of the adenosine A2 A receptor would be 
neurotoxic when cell damage is more severe due to the pathological accumulation of 
adenosine enhancing glutamate release. Adenosine A2 A receptor ligands might be of 
value in the treatment of neurodegenerative disorders.
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Effect of glutamate and adenosine A? a receptors on bone cell cultures.
There is increasing evidence that glutamate signalling occurs in bone. Excitotoxicity, 
therefore might underlie the increased osteoblastic cell death that occurs during 
disorders of bone remodelling such as osteoporosis. This project sought to examine |
if adenosine A2 A receptors could modulate this foiTn of cell death in MC3T3-E1 cells, 
an osteoblastic cell line.
Cells were characterised by assaying for alkaline phosphatase to ensure they 
differentiated in accordance with the literature. MC3T3-E1 cells cultured in media 
containing ascorbate and (3-glycerol phosphate showed an almost 2 -fold higher 
alkaline phosphatase activity than cells cultured in media without these supplements
(p<0 .0 1 ).
Cell viability was assessed by Alamar Blue reduction. Exposure of MC3T3-E1 cells 
to 100 pM and 300 pM NMDA caused a time- and dose-dependent increase in their 
viability (p<0.05, n=3). However, a prolonged exposure (72 hr) of MC3T3-E1 cells 
to NMDA did not induce an increase in their viability.
NMDA (100, 300 & 1000 pM) increased alkaline phosphatase activity in MC3T3-E1 
cells, an effect which AP5 tended to reduce.
Quinolinic acid (QA 300, 1000 & 3000 pM) induced a time and dose dependent 
increase in MC3T3-E1 cell viability (p<0.01, n=3). However, a prolonged exposure 
(72 hr) of MC3T3-E1 cells to 3000 pM QA did not induce an increase in their 
viability.
QA (300 & 1000) increased alkaline phosphatase activity in MC3T3-E1 cells, an 
effect which AP5 tended to reduce. However, 3000 pM QA did not increase alkaline 
phosphatase activity.
CGS 21680 alone elicited an increase in MC3T3-E1 cell viability. ZM 241385 alone 
elicited an increase in MC3T3-E1 cell viability (p<0.05, n=6 ). CGS 21680 induced a 
greater increase in cell viability when it was combined with ZM 241385 than it did 
alone.
CGS 21680 increased alkaline phosphatase activity in MC3T3-E1 cells, an effect 
which ZM 241385 trended to reduce.
Hydrogen peroxide (1000 pM) dramatically reduced cell viability in MC3T3-E1 cells 
(p<0.001, n=6 ). However, 10 and 100 pM hydrogen peroxide were without effect. 
NMDA, QA, CGS 21680 and ZM 241385 had no effect on the response to hydrogen 
peroxide. However, 100 pM H 2 O2  significantly reduced the proliferative effect of 
the CGS 21680 and ZM 241385 (p<0.05, n=6 ).
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Serum withdrawal increased the number of MC3T3-E1 cells positively 
immunostaining for caspase-3 (p<0.05). Cells positively staining for caspase-3 also 
displayed distinct chromatin condensation and cell shrinkage. CGS 21680 & ZM 
241385, the adenosine Pi receptor agonist cyclopentyladenosine and quinolinic acid 
had no effect on the expression of caspase-3.
In summary, the data confirm that glutamate acts as a trophic factor in bone cell 
development via the NMDA receptor (Taylor & Skerry, 2001) and that these cells do 
not succumb to excitotoxicity, at least on a short exposure to excitotoxins. 
Adenosine A2 A receptors have a trophic effect on MC3T3-E1 cell development. 
Further research into the molecular pharmacology of glutamate and adenosine 
receptors in bone cells is required. However, it is suggested that NMDA and 
adenosine A2 A as well as the kynurenine pathway could offer a therapeutic target in 
disorders of bone cell remodelling such as osteoporosis.
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1. Introduction.
1.1. Glutamate.
Glutamic acid is the most abundant transmitter in the mammalian central nervous 
system, accounting for up to 50% of all rapid excitatory synapses in the CNS (Stone 
& Burton, 1988; Nakanishi et ak, 1998). It mediates its diverse physiological effects 
via two main classes of receptor, ionotropic and metabotropic. lonotropic glutamate 
receptors have been defined by their prototypic agonists, namely the N-methyl-D- 
aspartate (NMDA), the a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid 
(AMPA) and the kainate receptors. Metabotropic glutamate receptors (of which 
there are 9) are G-protein coupled receptors (Nakanishi et al., 1998). In recent years, 
it has been revealed that signalling by glutamate also occurs in peripheral tissues, one 
of which is bone (Genever & Sken-y, 2001).
1.1.1. The NMDA receptor.
This receptor, like other ligand-gated ion channels is thought to be a heteroligomeric 
protein (Yakamura & Shimoji, 1999). It is composed of an NRl subunit and at least 
one isoform of the NR2 subunit and possibly NR3 subunits. The receptor has a high 
unitary conductance, is permeable to Na"^  & Ca '^  ^ (influx) and (efflux) and exhibits 
a voltage dependent block by Mg '^  ^ under resting conditions (Yakamura & Shimoji,
1999). This latter feature endows the receptor with a state-dependent activation
mechanism allowing it to underlie plastic phenomena such as long term potentiation I
in the CNS.
1.1.2. Kynurenines.
•;Glutamate is not the only endogenous ligand for the NMDA receptor. Another is "
quinolinic acid (QA), an intermediate along the kynurenine pathway (Stone, 1993;
2001) which metabolises over 90 % of dietary tryptophan which is not used in protein 
synthesis to generate the essential cofactors nicotinic acid and NAD.
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QA has a preference for NR2A & 2B containing NMDA receptors (Carvalho et al., 
1996). Although not as potent a neuroexcitant as NMDA, it is almost as potent a 
neurotoxin due to its effects on glutamate release and uptake (Tavares et al., 2002), 
mitochondrial function and generation of reactive oxygen species. This molecule is 
not the only member of the metabolic pathway active at glutamate receptors. 
Kynurenic acid was found to behave as a broad spectrum glutamate antagonist soon 
after the excitatory properties of QA were discovered in the early 1980s. It has since 
been established that the compound has an especially high affinity, in the low 
micromolar range, as antagonist at the strychnine-resistant glycine co-agonist site on 
the NMDA receptor (Stone, 1993). This feature has led to kynurenate being the lead 
compound for use in a range of CNS disorders (Stone, 1993).
1.2. Ischaemia.
Ischaemic stroke occurs due to a transient or permanent reduction in cerebral blood 
flow that is restricted to the territory of a major brain artery (Dirnagl et al., 1999). 
The reduction in flow is, in most cases caused by the occlusion of a cerebral artery 
either by an embolus or by local thrombosis. With an incidence around 250-400 in 
100000 and a mortality of rate of around 30 %, stroke remains the third leading cause 
of death in industrialized countries (Dimagl et al., 1999). In the USA alone, four 
million survivors are coping with its debilitating consequences (Dimagl et al., 1999). 
Despite numerous encouraging preclinical data, there has only been one successful 
clinical trial to date so an effective treatment for the condition is still necessary (De 
Keyseretal., 1999).
1.2.1. The excitotoxic cascade.
Glutamate needs to be kept at resting levels of < 1 jiM to mediate the crucial 
physiological functions of neuronal growth and development and synaptic plasticity. 
However brain tissue has a relatively high consumption of oxygen and glucose and 
depends almost entirely on oxidative phosphorylation for energy production 
(Kmjevic, 1999).
16
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Figure 1. Simplified overview of pathophysiological mechanisms in the 
ischaemic brain. Energy failure leads to the depolarisation of neurons. 
Activation of specific glutamate receptors dramatically increases intracellular 
Ca^^, Na"^  and Cl' levels while is released into the extracellular space. 
Diffusion of glutamate (GLU) and into the extracellular space can 
propagate a series of waves of depolarisation (peri-infarct depolarizations). 
Water moves into to the intracellular space via osmotic gradients and cells 
swell. The universal intracellular messenger Ca^^ overactivates numerous 
enzyme systems (proteases, lipases, endonucleases etc.). Free radicals are 
generated which damages membranes, mitochondria and DNA, in turn 
triggering caspase-mediated cell death (apoptosis). NO=nitric oxide. Modified 
from Dirnagl et al., (1999).
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Thus, focal impairment of cerebral blood flow restricts the delivery of substrates, 
particularly oxygen and glucose and impairs the energetics required to maintain ionic 
gradients. With energy depletion, membrane potential is lost and neurones and glia 
depolarize. As a result somatodendritic and presynaptic voltage dependent Ca^^ 
channels activate, spilling glutamate into the extracellular space (Small et al., 1997).
At the same time, the energy dependent processes, such as presynaptic reuptake of 
excitatory amino acids are impeded, further increasing the accumulation of glutamate 
into the synaptic cleft.
Activation of AMPA/kainate receptors (Weiss and Sensi, 2000) allows Ca^ "^  entry 
through these receptors as well as depolarizing the cell enough to remove the Mg  ^
block of the NMDA receptor (Kumamoto, 1996). Entry via this receptor-channel 
complex is the main source of cytoplasmic Ca^ "^  entry but metabotropic glutamate 
receptors also play their part via phospholipase C and Ins(l,4,5) P 3 signalling in 
inducing intracellular Ca^^ overload (Sattler and Tymianski, 2000).
Other ions such as Na"^  and Cl' enter the neurones via channels for monovalent ions 
(e.g. the AMPA receptor channel). Water then follows passively as the influx of Na“^ 
and C r is much larger than the efflux of K^. The increase in the ubiquitous second 
messenger, Ca^^ (Sattler and Tymianski, 2000) is thought to initiate a series of 
cytoplasmic and nuclear events that impact the development of tissue damage 
profoundly. These include activation of proteolytic enzymes that degrade cytoskeletal 
proteins, for example actin and spectrin (Furukawa et al., 1997) as well as 
extracellular matrix proteins such as laminin (Chen and Strickland, 1997).
■■'V
Activation of phospholipase A 2 and cyclooxygenase generates free radical species that 7
overwhelm endogenous scavenging mechanisms, producing lipid peroxidation and
membrane damage. Nitric oxide synthesised by the Ca^^ dependent enzyme,
neuronal nitric oxide synthase (NOS) reacts with a superoxide anion to form the s
highly reactive species, peroxynitrite that induces tissue damage. In contrast,
increased production of nitric oxide by endothelial cells can protect the tissue by li
improving the microcirculation (ladecola, 1997).
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Mitochondria, which are an important source of reactive oxygen species are impaired 
by free radical mediated disruption of the inner mitochondrial membrane and the 
oxidation of proteins that mediate electron transport, extrusion and ATP 
production (Dugan and Choi, 1994). The mitochondrial membrane becomes leaky, 
partly owing to the formation of a mitochondrial permeability transition pore, which 
promotes mitochondrial swelling, the cessation of ATP production and an oxygen free 
radical burst. Cytochrome C is released from mitochondria and provides a trigger for 
cell death. V
1,3. Adenosine.
Catabolic activity of several major metabolic pathways leads to the production of 
adenosine (Fredholm, 1997). Extracellularly this purine is widely present in 
mammalian organisms, especially in the CNS, heart and blood vessels. At rest 
extracellular ecto-5’-nucleotidases provide another significant source by converting 
released adenine nucleotides to adenosine (Von Lubitz, 1999). However, during 
metabolic stress induced by elevated neuronal electrical activity, hypoxia or ischemia 
the bulk of adenosine originates from the intense degradation of ATP. During 
ischemia the concentration of the purine increases 30-100 times above the resting 
level of about 100 nM (Von Lubitz, 1999).
1.3.1. Adenosine A 2A receptors.
Adenosine acts on 4 G-protein coupled receptors, namely Ai, A2 A, A2 B and A3 
receptors. The A2 A receptor is the high affinity A2  receptor and couples mostly to Gs 
but also to Gi/Go and G 1 2 /1 3  (Moreau & Huber, 1999; Cunha, 2001). A number of |
selective ligands are available to explore the function of the receptor. The majority of 
A2 A selective agonists are 2-substituted adenosine derivatives or analogs (see Muller,
2000 for a recent review). The rank order of potency of these compounds is 2- 
hexenyl-5-N-ethyl carboxamido adenosine (NECA) > 2-p-(2-
carboxyethyl)phenethylamino-5 ’ ~N~ ethylcarboxyamidoadenosine hydrochloride 
(CGS 21680) > chloroadenosine (CADO) > cyclohexyladenosine (CHA), with CGS 
21680 being the most selective.
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However caution should be exercised with the use of CGS 21680 as although it is 
often referred to as being “A2 A selective”, it only shows moderate affinity (19 nM at 
rat, 27 nM at human A2 A receptors) and is quite potent at rat, and particularly at 
human, A3 receptors (Muller, 2000). Therefore CGS 21680 is only 30-fold selective 
for A2 A receptors in rat and virtually non-selective in humans. Other potent A2 A 
agonists that have been developed are non-selective since they also exhibit high 
affinity for A3 receptors as well and some of them are also very potent at Ai receptors. 
So far no satisfactory adenosine A2 A receptor selective agonist is available (Muller, 
2000).
The adenosine A2 A receptor has a range of neuromodulatory effects which can 
influence neuronal viability (Table 1, p.23). On the detrimental side it is known that 
the adenosine A2 A receptor inhibits A% receptors (Cunha, 2001). Furthermore, the 
adenosine A2 A receptor can preferentially elicit excitatory amino acid release over 
inhibitory amino acid release from rat cerebrocortical synaptosomes (Marchi et al.,
2002) and can also increase glial glutamate efflux (Li et al., 2001). Antagonism of 
this action most probably underlies the neuroprotective effect of A2 A receptor 
blockade which has been demonstrated in vivo. In the striatum, it has been shown 
that the A2 A receptor can inhibit evoked GAB A release (Kirk & Richardson, 1995).
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The most commonly used A2 A antagonists are [9-chloro-2-(2-furanyl)-5,6-dihydro- 
1,2,4-triazolo (1,5-c) quinazolin-5-imine] (CGS 15943), 4-(2-[7-amino-2-[2- 
furyl][l,2,4]triazolo[2,3-a][l,3,5]triazo-5-yl-amino]ethyl)phenol 
ZM 241385 and 5-amino-7-(2-phenylethyl)-2-(2-furyl)~pyrazolo [4,3-e]-l,2,4-triazolo |
[1,5-c] pyrimidine (SCH 58261) (Moreau & Huber, 1999) and a study by Ongini and 
colleagues (1999) sought to evaluate whether these antagonists were “A2 A selective” 
and which one was the most useful in this regard. CGS 15943 had micromolar 
affinity for the receptor, however, its A2 A vs. Ai selectivity was negligible, thus 
caution should be exercised with the use of this agent. ZM 241385 and in particular 
SCH 58261 showed good A2 A selectivity so this latter compound should be the 
prefened antagonist.
1.3.2. Adenosine A 2A receptors and neiiroprotection.
However, this effect may only be a feature of receptors from this brain region which 
have been proposed as being atypical due to their enhanced Gs coupling (Sebastiao & s[
Ribeiro, 1996).
It is clear that the neuroprotection paradoxically also seen with the adenosine A%A 
receptor activation in vivo can be attributed to effects on cerebral blood flow, glucose 
utilization, platelet aggregation and superoxide generation from neutrophils (see e.g.
Jones et al., 1998a). However, it is known that the adenosine A%A receptor can 
enhance evoked GAB A release from hippocampal synaptosomes (Cunha & Ribeiro,
2 0 0 0 ) which could lead to a general attenuation of neuronal excitability and so limit 
cell death during an ischaemic insult.
Futhermore, it is now becoming clear that the adenosine A2 A receptor has a wide 
range of intracellular effectors which can influence neuronal excitability and viability.
For example, in the striatum it has been shown that this receptor can couple to G. and 
in this brain region CGS 21680 inhibits the conductance of NMDA receptor channels, 
by a mechanism that involves the PLC, IP3 , calmodulin and calmodulin II kinase 
pathway (Wirkner et al., 2000). The adenosine A2 A receptor can also inhibit N-type g
calcium channels in PC 12 cells (Park et al., 1997). Furthermore, Haynes (2000) 
showed that the receptor causes ATP-sensitive potassium channel (Katp) and large 
conductance potassium activated calcium channel (BKca) activation in the rat 
epididymis so if the same effector activation occurs in the CNS, it could exert a 
hyperpolarizing effect on neurons and so limit their cell death during an excitotoxic 
insult. Furtheraiore, in PC 12 cells it is known that adenosine A2 A receptors have a 
close synergistic relationship with growth factors, especially NGF (Arslan et ak,
1997; Arslan & Fredholm, 2000). Also, microglial NGF is enhanced by adenosine 
A za receptors (Heese et ak, 1997) and this relationship might occur in other brain 
cells as well. Finally, it has recently been revealed that adenosine A za receptors can 
directly activate Trk neurotrophin receptors in the absence of neurotrophins (Lee et 
ak, 2 0 0 2 ).
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Table 1. Potential mechanisms by which A%A receptors could modulate neuronal 
viability in cortical neuronal cultures.
Beneficial. Reference.
i  NMDA conductance via PLC, IP3 , Wirkner et al., 2000.
calmodulin and CamKII activation
i  N-type Ca^^ channel conductance via Park et al., 1997.
PKA activation
t  K atp + BKca conductance via PKA and Haynes et al., 2000.
G activation
t  neurotrophin activity Arslan et al., 1997; Arslan & Fredholm, 2000; 
Heese et al., 1997; Lee, Ragapogal & Chao, 
2 0 0 2
Detrimental.
T K^ stimulated Glu release from neurons Mai'chi et al., 2002; Cunha, 2001.
via PKC modulation of P-type Ca^^
channels
i  G ABA release via PKA & PKC Kirk and Richardson, 1995; Cunha, 2001.
activation
i  Ai receptor activity via PKC activation Cunha, 2001.
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2.3.3. Adenosine Aza receptors and apoptosis.
It is generally accepted that at low concentrations adenosine induces cellular 
proliferation whereas high concentrations induce apoptosis of a variety of cell types 
(Rathbone et ah, 1999). Some recent studies examining the role of the adenosine 
A2 A receptor in apoptosis of blood cell types have given conflicting results with 
adenosine A2 A receptor activation observed to enhance (Barbieri, 1998; Apasov;
2000) apoptosis. However, Huang and colleagues (2001) showed that the adenosine
A2 A receptor was capable of protecting against apoptosis in PC 12 cells. Very
recently, it has been demonstrated that A2 A receptors are capable of protecting against g
apoptosis induced by growth factor withdrawal in hippocampal neurons by direct
activation of Trk B receptors in the absence of neurotrophins (Lee & Chao, 2001).
1.4. The basic multicellular unit and bone remodelling.
For centuries the skeleton has been recognised as a means of locomotion, protection 
of vital organs and provision of a readily available store of calcium and phosphorus.
However, it is only comparatively recently has it been appreciated that bone is a
dynamic tissue that is constantly remodelling itself, a process carried out by two main
types of cells: osteoclasts and osteoblasts. The former erode cavities in bone and the S
latter then synthesize new bone matrix, all to the single purpose of bone renewal.
Remodelling or turnover is carried out by juxtaposed osteoclasts and osteoclasts 
comprising temporary anatomical structures known as basic multicellular units 
(BMUs) (Weinstein & Manolagas, 2000).
1.4.1. Bone remodelling.
Bone turnover starts by conversion of an inactive skeletal surface to a remodeling site, 
a process known as activation. This involves proliferation of new blood vessels 
needed to bring recruited resorbing cells to the remodelling site and retraction of the 
flat, pavement-like cells that cover inactive surfaces to expose the mineralized bone 
surface. The recruited cells become multinucleated osteoclasts, which attach to the 
newly exposed bone surface with a ring of contractile proteins, sealing off a 
subosteoblastic resorption compaitment.
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-The osteoclasts then secrete lysosomal enzymes, hydrogen ions and collagenase from 
their basement membrane to form a resorption bay or cavity (Parfitt et ah, 1981).
After the cavity is formed, the osteoclasts detach from bone and move away to a new 
resorption site. When the osteoclasts have moved away, osteoblasts are brought in to 
reconstitute the previously resorbed cavity with new bone, a process known as 
coupling. During the 6  to 9 month lifespan of a BMU, the shorter lived osteoclasts 
and osteoblasts require continual replacement while maintaining the same discrete 
spatial and temporal relationships to each other as the BMU digs through the bone. 
By this means, the adult skeleton, containing approximately 35 million bone structural 
units or BSUs (one from each previous BMU) is almost completely regenerated every 
10 years (Conal et ah, 1998). In healthy human adults, 3 to 4 million BMUs are 
initiated each year and approximately 1 million are operating at any one time.
1.5. Disorders of bone remodelling.
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One of the most prevalent disorders of bone remodelling is postmenopausal 
osteoporosis. The condition is characterized by low bone mass and 
microarchitectural deterioration of the skeleton leading to an increased risk of fracture
•■jafter minimal trauma. It is the most common form of osteoporosis and the most 
common of all systemic osteopathies. Annually, in the U.S. alone, the loss of bone in 
the disorder results in approximately 300,000 hip fractures and $9 billion in direct 
medical costs (Bason, 1996). These fractures result from the accelerated loss of bone 
that occurs in women after natural or surgically induced menopause.
1.6. Mechanisms of cell death.
1.6.L Necrosis.
Traditionally, cell death has been classified, based on morphological criteria as being 
either necrotic or apoptotic (Wyllie et ah, 1980). Necrosis is in general, a form of •icell death that rapidly occurs in response to severe insults such as anoxia and cell 
trauma and is associated with alterations in calcium and sodium ion homeostasis. The 
main moiphological changes in cells undergoing necrosis include cellular and 
organellar swelling, especially the mitochondria.
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Subsequently there is a dissolution of organelles, rupture of the plasma membrane 
with leakage of cellular contents in to the extracellular space and random DNA 
degradation following histone proteolysis. This form of cell death usually affects 
large groups of adjacent cells and is associated with an inflammatory reaction.
1.6.2. Apoptosis.
In contrast, apoptosis is a delayed foina of cell death resulting from less severe insults 
and is associated with activation of a “genetic program”. Cells undergoing this fonn 
of cell death exhibit shrinkage of the cytoplasm and condensation of nuclear material 
into “clumps” (Banasiak, 2000).
As the process continues the nucleus undergoes fragmentation and the endoplasmic 
reticulum fuses with the plasma membrane forming vesicles and convoluting its 
surface. In the final stages of apoptosis, there is cellular fragmentation forming 
membrane-bound apoptotic bodies that contain intact cytoplasmic organelles and 
nuclear fragments.
1.7. Mechanisms of excitotoxic cell death.
It is now becoming clear that a binary scheme for classifying neuronal cell death is 
severely flawed as excitotoxic cell death often appears as neither apoptotic or 
necrotic. Thus, in cerebellar granule cells, Dessi et al. (1993) concluded that 
excitotoxicity is non-apoptotic as protein synthesis inhibitors and an endonuclease 
inhibitor (aurintricarboxylic acid) could not protect against cell death in these cells. 
Also, an interesting study by Chihab et al. (1998) showed that glutamate could not 
induce cell death in neurons less than 6 days old but at 13 days the cells underwent 
necrosis and not apoptosis. In contrast, Kure et al. (1991) concluded that 
excitotoxicity is an active suicide process as endonuclease and inRNA synthesis 
inhibitors prevented cell death. A study by Leist and co-workers (1997) 
demonstrated, using cerebellar granule cells, that nitric oxide donors elicit apoptosis 
by caspase activation.
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Although it is often assumed that cells die by necrosis when they are exposed to 
severe insults and by apoptosis when they are subject to mild trauma (Cheung et ah, 
1998; Banasiak et ah, 2000), excitotoxicity can be an exception to this. For example 
Gwag et ah (1997) showed that cultured murine cortical neurones exposed to low 
concentrations of NMDA, AMP A and kainate showed the classical moiphological 
features of necrosis. This theory is also backed up by in vivo studies mainly 
peifoimed by Martin and colleagues (1998). These authors observed that in newborn 
rats, excitotoxic activation of NMDA and non-NMDA glutamate receptors causes 
neuronal death with phenotypes ranging from apoptotic to necrotic. They observed 
“structurally different forms of dying cells: a classic apoptotic fonn, similar to the 
endocytic -autophagic type and a classic necrotic form”.
Also, when these authors examined the progression of excitotoxin-induced, neuronal 
apoptosis in the newborn brain, they observed that “the vacuolated fonn is a precursor 
stage of apoptosis with many similarities to programmed cell death occuning in the 
developing brain”.
1.7.1. Mechanisms o f quinolinic acid induced cell death.
It is becoming increasingly evident that pathological concentrations of QA 
encountered in the brain and cerebrospinal fluid in certain circumstances can cause 
neuronal damage as well. Although QA is not as strong a neuroexcitant as NMDA, 
it is almost as potent a neurotoxin as it can enhance glutamate release from neurons. 
Furthermore, QA can also inhibit uptake of the transmitter into glia (Tavares, 2002) as 
well as having the capacity to cause mitochondrial dysfunction, lipid peroxidation and 
generate free radical damage (Stone, 2001). In vitro studies have shown that 
micromolar concentrations of QA are toxic when exposed to cells for several hours 
(Kim & Choi, 1987; Khaspekov et al., 1990; Galanaga et al., 1990; Keilhoff & Erdo, 
1991; Chiarugi et al., 2001).
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Furthermore, corticostriatal cell cultures exposed to submicromolar concentrations of 
QA for several weeks are susceptible to excitotoxicity (Whetsell & Schwarcz, 1989).
Thus, excitotoxic cell death is not identical in every neuronal type as one would not 
expect it to be due to the high diversity in the expression, localization and function of 
glutamate receptor subtypes and second messenger systems. Furthermore, it seems 
that excitotoxicity should not be seen as either strictly apoptotic or strictly necrotic 
but exists as an intermediate or hybrid foim of cell death, lying along a structural 
continuum with apoptosis and necrosis at the extremes.
1.7.2. Mechanisms o f glutamate-induced apoptosis.
Various mechanisms and biochemical events have been implicated in glutamate- 
induced apoptotic changes. More recently, it has been shown that mitochondria are 
central in glutamate-induced cell death (Montai, 1998). For example, inhibition of 
calcineurin, (a calcium-calmodulin regulated phosphatase) prevents the collapse of 
mitochondrial membrane potential and apoptotic cell death (Ankarcrona et ah, 1996; 
Wang et ah, 1999).
Calcineurin dephosphorylates Bcl-xl/Bcl-2 associated death promoter (BAD) a pro- 
apoptotic gene product which is then translocated to the mitochondria to dimerize 
with B-cell lymphoma/leukaemia-xl (Bci-xl), a process that initiates apoptosis (Wang 
et ah, 1996, 1999). It is this dimerization that induces the release of cytochrome c 
from mitochondria and along with apoptotic protease activating factor-1 (Apaf-1) and 
pro-pro teases, proteases are formed and lead the way to cell death by apoptosis 
(Neame et ah, 1998).
1.7.3. Caspases.
Whereas BAD can initiate apoptosis, it is well recognized that the effector molecules 
are proteases, serine and cysteine proteases, termed caspases. However, recently, 
there has been extensive interest in the processes of cell death and controversy 
continues to surround the definitions that distinguish apoptosis from other forms of 
cell death.
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Because of this confusion in interpretation of these results, the definition of apoptosis 
has changed. It is defined as the process of cell death associated with caspase 
activation or caspase-mediated cell death and presumes that caspases represent its 
final common mechanistic pathway (Cohen, 1997).
Caspases are cysteine proteinases with two aspartate cleavage sites, one of which 
excises the prodomain and the other that cleaves the lai'ge domain from the small 
domain. Among the group of 14 caspases identified to date (2003), caspase-3 has 
been recognised as a central player in mediating apoptosis and is the most widely 
studied.
28
Caspases are synthesised and exist mostly in the cytoplasm of viable cells as an 
inactive pro-enzyme. Activation of caspase-zymogens is an early event in the 
process of apoptosis. In response to the release of cytochrome C from the #
mitochondria combining with Apaf-1 and pro-caspases (giving the apoptosome) pro- 
caspases are processed by enzymatic cleavage to generate active enzymes.
The p32 pro-enzyme of the protease first undergoes cleavage at the C-teiminal side of 
Asp^^ to remove the amino terminal pro-domain (Desagher & Martinou, 2000).
Additional cleavage at the C-terminal side of Asp^^  ^ results in the generation of the 
pI7 and p l2  fragments. The X-ray crystal structure of caspase-3 shows the 
foimation of a tetramer composed of two small and two large subunits. The tetramer 
has been suggested to be the catalytically active foim.
Both in vivo and in vitro data suggest glutamate induces caspase-3 induction in 
neurons (Du et al., 1997; Gottron et al., 1997; Tenneti et al., 1998; Tenneti & Lipton,
2000; Hirashima et al., 1999; Thomas & Mayle, 2000; Han et al., 2002; Lok et al.,
2002; Zhang et al., 2002). With regard to the cell death process induced by 
quinolinic acid, Chiarugi and colleagues (2001) demonstrated that caspase inhibitors 
did not prevent quinolinic acid-induced cell death in rat cortical cultures so these 
proteases might not play a role in mediating cell death induced by this molecule.
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The transcription factor AP-1 and the cellular counterpart of v-Jun (c-Jun) activation 
by its N-teiminal kinase Ink, especially Jnk-3 which is selectively expressed in the 
CNS are also critical as a Jnk-3 knock out protects mice from excitotoxic apoptosis 
(Tabuchi et ah, 1996; Yang et ah, 1997a, 1997b). Glutamate-induced apoptosis also 
can activate another pathway, that of p53, a tumour suppressor gene, that can lead to 
cell death by activating a Bax-related pathway in neurons (Uberti et al., 1998).
Hence, glutamate can lead to apoptosis by activating a number of processes that 
possibly converge into caspase activation. While it is not yet clear as to what are the 
gene products that constitute all the targets for caspases, it is clear now, from the 
preceding discussion, that caspases play a crucial role in activating cell death by 
apoptosis during excitotoxicity.
1.7.4. Caspase-3 induction and apoptosis in osteoblasts.
Only a few studies have addressed the role of caspase-3 induction in apoptosis in 
MC3T3-E1 cells, a cell line, derived from newborn murine calvariae which displays 
osteoblast-like chamcteristics after repeated passages and which was used in the 
present project (Quarles et ah, 1992). Chae and colleagues (2000; 2001) showed that 
staurosporine and hypoxia both cause activation of the protease in these cells.
1.8. The osteoblast.
As mentioned earlier, osteoblasts are the skeletal cells that synthesize and regulate the 
deposition and mineralization of the extracellular matrix of bone. The precursors of 
these cells are pluripotent mesenchymal stem cells, present in both red and yellow 
man'ow (Aubin & Liu, 1996). Based on a number of histological and morphological 
criteria, in vivo bone formation progresses through distinct developmental stages. 
These stages are:- 1) commitment of mesenchymally derived cells to the osteoblast 
lineage 2) mitogenic growth of osteoblast precursors 3) expression of the 
differentiated osteoblast phenotype and ultimately formation of mineralized 
extracellular matrix by postmitotic teiminally differentiated osteoblasts.
‘ft:
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1.8.1. Osteoblast proliferation.
The balance between cell populations in an organism is controlled by the rates of 
proliferation, differentiation and programmed cell death or apoptosis (Quarles, 1992). 
Bone foimation during bone development and remodelling necessitates stringent 
control of osteoblast proliferation and differentiation (Stein et ah, 1996). In vivo, 
proliferation of osteoprogenitor cells occurs for formation of the embryonic skeleton 
and expansion of the bone stem cell population. Differentiated osteocytes and 
osteoprogenitor cells are then rendered quiescent, the osteoprogenitor cells reinitiate a 
limited extent of proliferation on demand during skeletal remodelling or fracture 
repair.
An analogous requirement for proliferation (regulatory mechanisms) is observed in 
primary cultures of normal diploid osteoblasts (Aubin & Liu, 1996). Initially 
isolation of osteoblasts from in vivo environments to in vitro culture results in 
proliferation of cells. The exponential growth supports expansion of the osteoblast 
cell population.
Post-mitotic proliferation subsequently supports focal multilayering of bone forming 
cells and biosynthesis of the type 1 collagen matrix extracellular which establishes a 
bone tissue-like organization (Stein et ah, 1996). A limited extent of compensatory 
proliferation occurs in mature, mineralizing bone nodules in association with 
apoptosis and upregulated collagenase activity.
In MC3T3-E1 cells, the initial phase of osteoblast development is characterised by 
active replication of undifferentiated cells. In this regard, during days 1-9 in vitro 
subconfluent cultures display rapid increases in cell number and high rates of DNA 
synthesis. However by day 10, growth rates reach a plateau and DNA synthesis 
becomes negligible (Quarles et ah, 1992).
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1.8.2. Osteoblast differentiation.
During the initial period of differentiation in vivo, osteoblasts are responsive to 
physiological requirements for expression of genes that support competency for 
proliferation, cell cycle progression and extracellular matrix biosynthesis as well as 
those that suppress expression of postproliferative bone phenotypic genes (Stein et ah, 
1996).
The mature osteoblast phenotype is characterised by the ability of the cells to 
synthesize collagen type 1 and a wide variety of noncollagenous proteins such as 
osteocalcin, bone salioprotein, osteopontin, proteoglycans and hormone as well as 
growth factor receptors (Aubin & Liu, 1996). Expression of the bone/liver/kidney 
(also called tissue nonspecific) isoform of alkaline phosphatase is positively 
coiTelated with bone formation. It is accepted that as the specific activity of the 
enzyme in a population of bone cells increases there is a corresponding shift to a more 
differentiated state (Aubin & Liu, 1996).
1.8.3. Alkaline phosphatase
Alkaline phosphatase (ALP) is a ubiquitous, membrane bound tetrameric enzyme 
attached to glycosyl-phosphatidyl-inositol moieties on the outer cell surface and is 
commonly used as a marker of osteogenic development in vitro and in the clinic 
(Henthorn, 1996). It was first postulated by Robison (1923) that alkaline 
phosphatase plays a role in bone development, concluding that there is an “enzyme 
present in the ossifying cartilage of young rats and rabbits which rapidly hydrolyzes 
hexosemonophosphoric acid in yielding free phosphoric acid”. This enzyme is now 
known to be alkaline phosphatase.
Although the precise physiological role of alkaline phosphatase is still unknown, it 
has been hypothesized to be involved in the mineralization process. Its expression is 
partly transcriptionally regulated but there is little evidence for translational and post 
translational control (Henthom, 1996).
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In MC3T3-E1 cells, the expression of alkaline phosphatase is time, but not cell 
density, dependent and evident only at the onset of growth aiTest at about day 9 and is 
enhanced 2-fold by ascorbate and ^-glycerol phosphate (Quarles et ah, 1992).
Selective inhibition of ALP does not affect cell growth but decreases osteocalcin 
production, mineralized nodule formation and accumulation of matrix calcium 
phosphate (Suguwai*a et al., 2002). It is known that a variety of agents that have a 
trophic influence on MC3T3-E1 development increase the expression of alkaline 
phosphatase as measured by the extent to which the enzyme can release free 
nitrophenol from p-nitrophenylphosphate (e.g.Yada et al., 1994; Suzuki et al., 1998; 
Genever & Skeiny, 2001). Thus this enzyme definitely plays a role in mineralization 
by MC3T3-E1 cells.
1.8.4. Osteoblastic cell death.
Although cell renewal and cell death aie opposing processes, they are inexorably 
linked in bone, as both are essential for bone formation. After osteoclasts finally 
stop resorbing bone, they die by apoptosis and are quickly removed by phagocytes 
during the early portion of the reversal phase. However, during the longer lifespan of 
the osteoblasts more changes and choices arise.
A variety of mediators in the bone microenvironment can influence osteoblastic 
apoptosis. Thus, MC3T3-E1 cells undergo apoptosis in response to serum 
withdrawal or addition of tumour necrosis factor alpha (TNF-a) as indicated by 
TLÎNEL labeling and DNA fragmentation (Jilka et al., 1998). The potential role of 
nitrosative stress in the cell death mediated by TNF-a has been investigated.
Induction of nitric oxide synthase activity caused osteoblastic apoptosis and this was 
enhanced by pretreatment with TNF-a (Damoulis & Hauschka, 1997). Furthermore, 
both these agents promoted macrophage mediated cytotoxicity of MC3T3-E1 cells in 
co-cultures with macrophages (Damoulis & Hauschka, 1997).
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The role of oxidative stress in MC3T3-E1 development has also been assessed. 
Hydrogen peroxide (H2 O2 ) and xanthine oxidase are capable of inducing significant 
cell death in these cells as well as inhibiting their differentiation (Mody et al., 2001).
1.8.5. Postmenopausal osteoporosis and osteoblastic apoptosis.
The oestrogen loss that occurs during menopause causes an increase in interleukin-1, 
interleukin-6 and TNF-a production which mediate an increase in osteoblast and
J'iosteoclast numbers and consequentially an increased frequency of their activation 
(Jilka, 1998). As well as changes occurring in the number of bone cells, erosion of 
deeper than normal cavities also takes place. This increased remodeling alone causes 
a loss of bone mineral density, because bone resoiption is faster than bone foimation 
and new BMUs are less dense than older ones.
Also, if resorption penetrates through a trabecular structure, the substrate for the 
coupled bone formation is lost forever. In this way oestrogen deficiency removes 
some cancellous elements completely.
Concunent loss of cortical bone occurs by enlargement and coalescence of 
subendocortical spaces, a process resulting from deeper penetration of endocortical 
osteoclasts. This deeper erosion is explained by a loss of oestrogen action in 
promoting osteoclastic apoptosis (Hughes et al., 1996; Kameda et al., 1997; Raisz,
1996). Loss of this effect prolongs the lifespan of osteoclasts and increases their 
numbers 2 to 3-fold, thus accounting for the perforation of tabeculae and grinding 
away of endocortical margins.
As ovariectomy increases the turnover of murine vertebrae osteoblasts 10-fold and 
osteocytes 4-fold (Weinstein & Manolagas, 2000), this indicates that the accelerated 
loss of bone that occurs after oestrogen deficiency is not only from an increase in 
osteoclast number but also from an increase in osteoblast and osteocyte apoptosis. In 
fact, it has been suggested that up to as many as 65% of osteoblasts that originally 
assemble at the remodelling site die by apoptosis before refilling the erosion cavity 
(Jilka et ah, 1998).
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1.9. Glutamate and bone cell development.
Over the past few years it has become evident that glutamate signalling may occur in 
bone. On the whole, this occurs in the same manner as in the central nervous system 
(reviewed by Skeiny & Taylor, 2001). Thus, osteoblasts express the whole range of 
glutamate receptors which display the same electrophysiological characteristics as 
their neuronal counterparts. They also express glutamate transporters as well as the 
exocytotic machinery needed for complete glutamate release.
Not surprisingly, the precise function of glutamate receptors in bone is still being 
evaluated. However, it is known that bone cells need to undergo changes in mass in 
response to exercise for example. Glutamatergic transmission could play a vital role 
in these skeletal adaptations, not only as a trophic factor but also perhaps by induction 
of a long term potentiation-like process (Skerry & Taylor, 2001).
1.9.1. The role o f glutamate in bone cell viability.
There are, however, some important differences between glutamate signalling in bone 
and central nervous system glutamatergic function. So far excitotoxic effects have 
not been demonstrated in bone cells and indeed all the evidence suggests that this 
neurotransmitter acts as a trophic factor in osteoblast development even at 
concentrations which are neurotoxic in the CNS (Genever & Skeny, 2001). 
Glutamate release parallels alkaline phosphatase activity (Bhangu et ah, 2001), 
suggesting that as MC3T3-E1 cells differentiate they express more of a glutamate 
phenotype. Also, attenuation of glutamate release by riluzole is able to inhibit 
alkaline phosphatase activity and at higher concentrations can induce apoptosis in 
MC3T3-E1 cells. Therefore, glutamate also has a trophic role in MC3T3-E1 cell 
development. Furthermore, glutamate at a concentration of 50 pM -  ImM increases 
the survival rates of human primary osteoblasts exposed to TNF-a & IFN-y (Genever 
& Skerry, 2001).
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Also, unlike in the CNS, glutamate release is negatively regulated by voltage- 
dependent calcium entry as a continued depolarization with 30-60 mM KCl inhibits 
glutamate release (Genever & Skeiny, 2001). However, in the CNS, glutamate can 
elicit neuronal damage partly via free radical release. In addition, quinolinic acid, a 
glutamatergic ligand and speculative endogenous central neurotoxin, at concentrations 
which are by itself not injurious to neurons, can be excitotoxic to hippocampal 
neurons in vivo in the presence of donors of nitrosative and oxidative stress (Behan &
Stone, 2002). As mentioned earlier (p. 32) nitric oxide enhances TNF-a induced Icytotoxicity in MC3T3-E1 cells (Damoulis & Hauschka, 1997) and both these 
molecules increase macrophage mediated death of these cells. Therefore, it is #
possible that in the presence of oxidative and nitrosative stress these mechanisms 
occur in osteoblasts as well and glutamatergic ligands such as quinolinic acid could 
have a toxic action on MC3T3-E1 cells.
1.10. Cell culture systems for the assessment of cytotoxicity.
In vivo data have shown that both adenosine A2 A receptor agonists and antagonists are 
neuroprotective. It is known that activation of Az receptors increases cerebral blood 
flow and inhibits platelet aggregation (Stella et al., 1996; Hourani, 1996). These 
effects would increase blood and nutrient supply to any ischaemically compromised 
area of the brain. Furthermore, adenosine A za receptor activation depresses cerebral 
glucose utilization in the cortex (Nehlig et ah, 1994), which may be advantageous to 
neuronal viability by decreasing the requirement for depleted nutrients during 
ischaemia. Furthermore, activation of adenosine A z a  receptors decreases superoxide 
anion production in neutrophils (Cronstein et ah, 1985). If the same action occurs in 
neurons, it is possible that adenosine A 2A receptor activation could reduce free radical |
associated cell damage which occurs in ischaemia and excitotoxicity (Lafon-Cazal et 
ah, 1993; Reynolds & Hastings, 1995; Patel et ah, 1996). Therefore activation of 
adenosine A2 A receptors could exert neuroprotection in vivo by peripheral 
mechanisms of action. However, it is possible that the adenosine A2 A receptor also 
exerts a direct neuroprotective effect, because, as detailed in Table 1 (p.22) the 
receptor has a wide range of neuromodulatory effects which could be beneficial to 
neuronal survival during an excitotoxic insult.
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Therefore, in order to eliminate the role of central vs. peripheral mechanisms of A2 A 
receptor activation in the neuroprotection demonstrated in vivo and to establish the 
direct neuromodulatory role of the A2 A receptor on neuronal viability it is necessary to 
have a system that consists entirely of this cell type.
As stated by Harry et al. (1998) 'Tn vitro tests have their greatest potential in 
providing information on basic mechanistic processes in order to refine specific 
experimental questions to be addressed in the whole animal”. In other words, an in 
vitro model of excitotoxicity is needed.
There are two main systems which could provide an in vitro model of excitotoxicity. 
These are primary cultures or the use of a cell line. According to Harry et al. (1998), 
primary cultures are “cells harvested directly from the organism, dissociated in to 
single cells before seeding into the culture vessel, and maintained in vitro for periods 
exceeding 24 hours”. Cell lines, however are “cultures that have been serially 
transplanted or subcultured through a number of generations and can be propagated 
for an extended period of time”. Whether a primary culture or cell line should be 
used as the in vitro system depends upon a number of factors. Although neuronal 
cell lines are available, they are generally derived from endogenous tumours or from 
chemically or virally transformed cells and so often have an atypical nature when 
established in culture (Lowndes et ah, 1994). Although some cell lines (e.g. 
phaechromocytoma) are useful for examining peripheral neuronal cell death, central 
neuronal cell lines are expensive, difficult to set up and maintain.
1.10,1. Primary cell cultures.
For these reasons, primary cell cultures are the prefeined system for use in excitotoxic 
studies. Also, it is generally accepted that they more closely represent the in vivo 
situation (Buchhalter & Dichter, 1996). The most frequently used primary cell 
cultures for this purpose are cortical, cerebellar granule and hippocampal cultures. 
Which tissue should be cultured depends really upon the investigator’s personal 
preference as there seems little to tell between receptor expression for the “classic” 
neurotransmitters between these brain areas.
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The cortex and cerebellum are much larger than the hippocampus and so it is possible A:to plate many more testable cultures when these brain regions are cultured (Cambray- 
Deakin, 1995). However, as the hippocampus is often used for electrophysiological 
studies, some laboratories prefer to use hippocampal cultures too to see if a certain 
electrophysiological property extends to neurotoxicity (Buchhalter & Dichter, 1992).
I
1.10.2. Cell lines.
è1
Continuous cell lines are transformed cells derived from tumourigenic tissue which 
have a life span of approximately 50 divisions. Cell lines of limited life span often 
undergo crisis after which their growth potential changes and their lifespan becomes 
unlimited. The major attributes of clonal cell lines cell are homogeneity and the ease 
of which a large quantity of cells can be grown. Features of established cell lines 
include the ability to undergo an unlimited number of cell divisions, altered cell and 
colony morphology, lack of locomotion, lack of contact inhibition, lack of density- 
dependent inhibition of cell multiplication, loss of anchorage dependence and high 
fibrinolytic activity (Diamond & Baird, 1997). In addition, once the phenotype of the 
cell line is established, it does not change. However, it has been observed quite often 
that the cells can “drift” with regai'd to physiological responsiveness with increased 
passages (Harry et al., 1998).
Information about regulation of osteogenesis is incomplete, partly because of the lack 
of reliable in vitro models to study the developmental sequence associated with 
replication of osteoblast precursor and differentiation. There are a number of cell 
lines available for the investigation of bone foimation in vitro. Malignant osteoblast 
(transformed) cell lines, although of uniform phenotype, have unrepressed replicative 
activity and fail to display the noimal coupling of differentiation and growth ainest 
(Pardee et ah, 1978). The simultaneous expression of partially differentiated and 
replicative function severely limit such transfonned cell lines as models to study the 
process of osteoblast development. Studies in primary osteoblast cultures support the 
concept of sequential expression of the osteoblast phenotype, but inteipretation of 
these data is limited by the presence, in isolated calvarial and primary cell cultures, of 
various cell populations at various developmental stages, as well as de-differentiated 
cell subpopulations.
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Also, subcultivation of primary cultures results in loss of osteoblast specific 
characteristics (Aronow et ah, 1990). An understanding of the osteoblast 
developmental sequence has been greatly facilitated by an immortalized cell culture 
system that permits independent investigation of osteoprogenitors, osteoblast 
differentiation and mature osteoblast function. The MC3T3-E1 cell line, derived 
from newborn murine calvariae displays osteoblast-like characteristics after repeated 
passages (Quarles et ah, 1992).
1.10.3. MC3T3-E1 cells.
Sudo et ah (1983) demonstrated that this cell line expresses parameters of the 
osteoblast phenotype, including type 1 collagen synthesis, alkaline phosphatase and 
nodular extracellular matrix mineralization resembling woven bone. Quarles et ah 
(1992) furthered these observations by revealing that in culture these cells show a 
temporal sequence of development characterized by distinct proliferative and 
differentiated stages.
rJ-
The initial stage of development of the cells is characterized by cell proliferation and 
high levels of type 1 collagen expression, biosynthesis and secretion but the cells 
remain undifferentiated as evidenced by low levels of alkaline phosphatase activity. ftThey also have an inability to effectively assimilate newly synthesised collagen into 
extracellular matrix and the absence of mineralization (Stein et ah, 1996).
Downregulation of replication and expression of differentiated osteoblast functions 
characterize the next developmental stage which occurs 10 days after plating. At this 
time, increases in alkaline phosphatase activity -  a characteristic of the osteoblast 
phenotype and acquisition of specialized bone function consisting of collagen 
deposition into an extracellular matrix occur. A final phase of MC3T3-E1 maturation 
begins about day 20 and is defined by matrix calcification associated with progressive 
increases in extracellular matrix accumulation and alkaline phosphatase activity (Stein 
et ah, 1996).
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The effects of ascorbate and (3-glycerol phosphate (BGP) on the differentiation of 
these cells have also been examined (Quarles et ah, 1992). In the absence of these 
agents MC3T3-E1 cells attain growth arrest and express low levels of alkaline 
phosphatase at day 10. However, at this stage, they fail to express a fully 
differentiated osteoblast phenotype as evidenced by the inability to form and 
mineralize extracellular matrix. Ascorbate facilitated the expression of osteoblast 
phenotype in these cells, without affecting the timing of maturation. Addition of 
ascorbate to the culture medium significantly increases cellular alkaline phosphatase 
activity in differentiated cells, whereas the time course of osteoblast phenotype 
development as defined by cessation of mitogenic growth and the onset of alkaline 
phosphatase expression were unaffected by ascorbate. These cells represent 
immature osteoblasts that undergo a temporal program consistent with osteoblast 
differentiation in stages analogous to in vivo bone formation.
1.10.4. Adenosine Aza receptors and MC3T3-E1 development.
Another mediator of bone remodelling in the osseous microenvironment alongside 
growth factors, cytokines and glutamate is adenosine. The purine has a mitogenic 
effect on MC3T3-E1 cells (Shimegi, 1996). With regard to the role of receptor 
subtypes for this purine in MC3T3-E1 cells, Shimegi (1998) showed that adenosine 
could by itself enhance MC3T3-E1 proliferation and interestingly also enhanced 
platelet derived growth factor induced mitogenecity in them. Cyclopentylxanthine and 
pertussis toxin (PTX) partly antagonized this proliferative effect confiiming that A] 
receptors partly mediated this action. However, as some of this mitogenicity was not 
xanthine and PTX sensitive, it is clear that other adenosine receptors played a part in 
eliciting this effect.
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1.11. Aims.
In vivo studies have demonstrated that both adenosine A2 A receptor agonists and 
antagonists are neuroprotective (Jones et ah, 1998 a,b). It is certain that some of the 
neuroprotection exhibited by the agonists is peripherally mediated (Jones et ah, 1998 
a,b) but the antagonists mediate their protection via a central mechanism.
However, in vitro studies are needed to clarify what the actual role of the adenosine 
A2 A receptor is in modulation of neuronal viability, in order to refine specific 
experimental questions in the whole animal (Harry et ah, 1998) as when ischaemia is 
mild the use of an A2 A receptor antagonist might block valuable protective A2 A 
receptor-mediated peripheral effects. Cortical neuronal cultures are an established in 
vitro model for examining the effects of neuroprotective agents. Thus, the primary 
aim of the project is to elucidate the direct role of the adenosine A2 A receptor in 
neuronal viability using this model. Furthermore, disorders of bone remodelling, 
such as postmenopausal osteoporosis and periodontal disease, are still in need of an 
effective treatment. As there is increasing evidence that glutamate signalling occurs 
in bone, it is not inconceivable that excitotoxicity might underlie the excess 
osteoblastic cell death that occurs in these conditions. Adenosine A2 A receptors 
might, therefore, be able to modulate osteoblastic as well as central excitotoxicity. 
Thus, a second aim of this project was to elucidate the role of the adenosine A2 A 
receptor in osteoblastic cell viability, using MC3T3-E1 cells, an established in vitro 
model of osteogenesis.
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2. Methods for the effects of glutamate and adenosine receptor ligands on 
neuronal cell cultures.
2.1. Animals.
2.1.1. Animal source.
Female rats (Wistar) were obtained from a commercial source (Harlan, U.K.). They 
were maintained by standard hygienic procedures and the behaviour and weight (450- 
550 g) of animals were monitored routinely to exclude them from disease.
2.1.2. Animal selection.
In excitotoxic studies using primary neuronal cultures, the rat has become the 
favoured species over the mouse probably because the microdissection involved in 
removing the tissue can be more easily performed on this species. Although some 
papers report using embryonic tissue from rats at a gestation period as early as 15 
days, in the present study, it was found the brain tissue from embryos of this age was 
too fragile to culture successfully. Therefore, dams of a gestation period of between 
17-19 days were used.
2.2. Microsurgery for the dissection of cortical tissue.
The following steps were all performed under sterile conditions. In a sterile laminar 
fiowhood, 50 ml of MEM (Gibco) was divided between a 140 mm diameter and a 35 
mm diameter Petri dish (Falcon, U.K.). 5 ml of a 25 % solution of urethane
intraperitoneally injected was used to sacrifice the pregnant animal. 70 % alcohol was 
sprayed over the abdominal region to minimize accumulation of fur during the 
dissection. A ventral incision was made about 1 cm below the sternum to the pubic 
symphysis. The gravid uterine horns were excised and the embryonic sacs detached 
where they attached to the placenta and placed in the lid of the 140 mm diameter Petri 
dish in one ml of MEM. Embryos were carefully removed from their sacs using 
forceps.
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Embryos were then decapitated using scissors and the heads placed in a 35 mm 
diameter Petri dish containing 2 ml of MEM. Cortical tissue was isolated as follows. 
The brain was gently squeezed from the cranium with forceps after making a small 
longitudinal incision in the middle of the skull. Using a stereobinocular dissecting 
microscope (previously swabbed with ethanol), the cortex or hippocampus was 
removed following the procedure of Hansson & Ronnback (1989), the meninges 
carefully removed using fine tip forceps and the tissue placed in a 35 mm diameter 
Petri dish containing MEM. The procedure was repeated using as many embryos, 
regardless of their sex as necessary to collect enough tissue. Typically, this was about 
10 embryos when the dam was at gestation day 17 and about 6 when at gestation day 
19.
2.3. Mechanical and enzymatic digestion of tissue.
A standard razor blade was used to mechanically disrupt the tissue until smaller 
pieces of it could not be obtained. As much of the tissue was then triturated using a 
wide tip plastic pipette and placed in a 15 ml centrifuge tube. The tissue was then 
washed twice in MEM by simply triturating the medium-tissue mixture with a fine tip 
pastette and allowing the tissue to settle. The tissue was enzymatically digested with 
0.4 % trypsin in MEM for 30 min at 37°C. This concentration and time of exposure 
of the enzyme was considered optimal after experience showed that 5 % trypsin for 40 
minutes resulted in complete cell lysis. This was evident as when plating the tissue 
after a 40 min trypsin treatment, cell debris and no viable neuronal network was 
observed even after several days in vitro. However, 0.25 % trypsin for 30 min 
resulted in insufficient digestion of connective tissue, which resulted in cell clumps 
and again, a lack of a viable neuronal network after several days in vitro. 0.4 % 
trypsin was prepared by adding a 1 ml aliquot of 2.5 % trypsin in phosphate buffered 
saline (PBS) (Gibco) to 5 ml MEM.
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2.3.1, Inactivation o f trypsin.
The enzymatic digestion was ended by adding 5 ml of foetal calf serum (FCS) to the 
centrifuge tube. To remove the trypsin and the FCS, the cells were resuspended in 
MEM using a fine tip pastette followed by centrifuging for 3-4 min at 500-700 i*pm 
(50 g). This procedure was repeated twice.
2.4. Cell seeding and plating.
2.4.1. Coating o f wells.
Laminin (Cambridge Bioscience, U.K.) and poly-D-lysine (PDL) (Sigma, U.K.) 
together represent a good substrate for neurite outgrowth in primary culture (see 
Buchhalter & Dichter, 1992; Paulsson, 1992). This substrate combination was used 
therefore as the coating for the eight well chamber slides. Solutions of the reagents 
were prepared as follows:- 4 mis of diethylpyrocarbonate (DEPC) treated distilled 
water was added to 5 mg of thawed (PDL). 128 pi of this PDL solution and 240 pi 
of thawed laminin (1 mg/ml.) were added to 40 ml of DEPC treated water in a Falcon 
tube to give final concentrations of 4 pg/ml for PDL and 6 pg/ml for laminin. The 
solution was applied to the plates the night before use and any remaining liquid 
aspirated off with a fine tip pastette on the morning of the dissection and the plates 
left to air dry for at least an hour prior to cell seeding.
2.4.2. Cell density.
Cells were seeded in DMEM (supplemented with 1% FCS and 100 lU/ml of penicillin 
and 100 pg/ml streptomycin (P/S) (Gibco)). The cell pellet was resuspended in 5 ml 
of culture media (preheated to 37°C). The density of viable neurons in this solution 
was determined by aliquotting 1 ml of cell suspension and incubating this with 100 pi 
of 4 % Trypan Blue solution (Sigma) at 37°C for 10 minutes.
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Two cell counts (minimum 100 cells/count) were performed using a haemocytometer 
at 400X magnification using a standard light phase microscope (Nikon), in order to 
calculate the percentage of viable neurons, defined as those excluding trypan blue. 
The volume of the resuspension solution was then adjusted to yield a seeding density 
of 200,000 to 500,000 cells/ml and the cells were then seeded using a mixing needle 
(Henley, U.K.) by the addition of 2 drops well. This gave a seeding density of
32.000 cells/well when the seeding density was 200,000/ml. and a seeding density of
80.000 cells/well when the seeding density was 500,000 cells/ml.
This seeding density of 200,000 to 500,000 cells/ml. was chosen after experience 
showed that when cells were seeded at a density below 200,000/ml they did not form 
a monolayer with extensive neuritic connections and arborizations at the time of their 
use in experiments (12-16 days in vitro). However, when seeded above a density of 
500,000/ml, cells had a tendency to detach before their use in experiments. Cells were 
examined to see if they had adhered at 24 & 48 hr after seeding. If this was the case, 
DMEM was replaced with Neurobasal (containing with 5 ml each of B27 supplement 
and penicillin/streptomycin antibiotics, Gibco) medium. This was changed every 2-3 
days thereafter. This serum free medium was chosen, as the maintenance medium as 
it has been shown that it virtually eliminates glial growth in primary neuronal cultures 
and is better in enhancing neuronal growth compared with serum containing media 
(Buchhalter & Dichter, 1992; Brewer, 1995).
2.5, Cell characterization.
2.5.1. Cell markers.
Despite the claims that Neurobasal medium eliminates glial growth (Brewer, 1995), it 
is essential that primary neuronal cultures are characterized as regards cell type. 
Immunocytochemistry offers a reliable and specific method for this (Barnstable, 
1992). Rabbit anti-neurofilament 200 (NF, Sigma) which recognises the 200 kD 
intermediate filament specific for neurons was chosen as the neural marker. Glial 
fibrillary acidic protein (GFAP, Sigma) was selected as the marker for astrocytes, as it 
is accepted that it is an unequivocal marker for this cell type (Juurlink & Hertz, 1992).
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Although it is possible to use certain antibodies, namely Ran-2, A2B5 and LBl 
(Marriott et ah, 1996) to distinguish between type-1 and type-2 astrocytes, it is 
generally appreciated that it is sufficient to label astrocytes with GFAP to distinguish 
them from neurons in primary cell culture (Juurlink & Hertz, 1992). Integrin cxM 
(Chemicon) was used for microglia detection (Milligan et ah, 1991) and 04  
(Chemicon) used for oligodendrocytes (Collarini, 1996).
2.5.2. The avidin-biotin-peroxidase complex (ABC) method.
The avidin-biotin system was first applied to immunocytochemistry for fluorescence 
microscopy in 1977 (Heggeness & Ash, 1977). The reaction between avidin and 
biotin by non-covalent bonds is very rapid, sensitive and stable and is one of the 
strongest bonds known in nature.
Biotin is conjugated to the secondary antibody by an indirect method and the antigen 
signals amplified. When the avidin-biotin-peroxidase complex (ABC) is added, a 
second amplification of antigen signals is completed. Therefore, the ABC method 
ensures maximal sensitivity in immunocytochemistry since an antibody can be coated 
with 150 biotin residues and each of them is able to conjugate with each ABC, 
ensuring a very high marker/antigen ratio (Coggi et ah, 1986). Peroxidase functions 
as a marker which catalyzes the chemical reaction of hydrogen peroxide and thereby 
allows staining visualization in the presence of di-azo-aminobenzene (DAB). In 
view of this sensitivity, the ABC method was chosen to examine the expression of 
mai'kers for the various brain cell types in this study.
2.5.3. Immunocytochemistry protocol.
A ll reasents used. These were prepared on day of use except phosphate buffer and 
phosphate buffered saline which were stored for up to 3 months at 4°C.
Phosphate buffer (PE: 0.2 M).
14.48g sodium dihydrogen phosphate (NaH2PO4.2H20) & 40.78g disodium hydrogen 
phosphate (Na2 HP0 4 ) in 2 L distilled water.
0.1 M PB was obtained by diluting an equal volume of 0.2 M PB with distilled water.
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Phosphate buffer solution (PBS (2X)).
36g sodium chloride (NaCl) & 200 ml PB & 1800 mis distilled H2 O.
4 % formaldehyde.
0.75 ml 36 % formaldehyde soin. + 6 ml O.IM PB.
0.2 % triton in PBS (XI ).
8 |il triton X-100 in 4 ml PBS (XI). This was achieved by slowly pipetting up the 
triton X-100, ensuring that the volume in the pipette was liquid only and free of air 
bubbles. When adding the triton X-100 mixture to PBS, care was taken to ensure that 
the total volume of liquid from the pipette tip was added by using a sharp and forceful 
push to expel the triton X-100 so that it foimed a snake like formation on being 
introduced into the PBS. It was ensured that the triton was fully dissolved in the PBS 
prior to its use by heating in a water bath for at least 10 minutes and vortexing the 
mixture 3 times.
I % hydrosen peroxide in methanol.
133 pi 30% hydrogen peroxide in 4 ml methanol.
20 % blocking serum (BS).
1.16 ml goat serum (GS, Diagnostics Scotland) and 4.64 ml PBS.
Primary antibody (1:100 diln. J.
12 pi stock primaiy antibody + 1188 pi BS.
Secondary antibody (1:200 diln. J.
600 pi GS and 15 pi stock secondary antibody + 2.385 ml PBS.
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ABC solution.
One drop A (avidin BH) and one di'op B (biotinylated horse radish peroxidase) added 
to 2.5 ml PBS (left for 30 min at room temperature before use).
DAB solution (Vector. USA).
To 5 ml distilled water, 2 drops of buffer stock solution were added. The entire 
solution was then mixed well. 4 drops of DAB stock solution were then added and 
the entire solution mixed well again. 2 drops of hydrogen peroxide solution were 
then added and the entire solution mixed well. Finally, 2 drops of nickel stock 
solution were added and the entire solution mixed well.
2.5.4, Procedure fo r fixing.
1. Fix sister cultures at same time of treatment with excitotoxins by rinsing with PB 
and then incubating them with 4% formaldehyde solution for 20-30 min at room 
temperature.
2. Rinse with PBS 3 times. Cells can be left in PBS for a few days before 
proceeding to immunostaining if necessary.
Working solutions for the primary antibodies mentioned above were prepared and 
tested over a range of concentrations. It was ascertained that NF and GFAP could be 
used at 1:500 in blocking serum. However, 0 4  and integrin otM were used at a 
dilution of 1:100.
2.5.5. Procedure for immunostaining.
Unless otherwise stated, the volume of reagent added to each well was 200 pl/well.
1. Rinse once with PBS.
2. Add 0.2 % triton X-100 in PBS (to enhance membrane permeability) for 10 min.
3.Wash 3 times with PBS.
4. Add 1 % H2 O2  in methanol (to block endogenous peroxidase) for 10 min.
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5. Wash 3 times with PBS.
6. Incubate with 20% blocking serum for 60 min. at room temperature (to block non- 
antigenic sites).
7. Remove blocking serum and incubate specimen with primary antibody (100 
pl/well) overnight at room temperature. Omit the primary antibody from 2 wells 
(control) to ensure the secondary antibody is reacting specifically with the primary 
antibody.
8. Wash 3 times with PBS.
9. Incubate cells for 60 minutes with 1:200 biotinylated goat anti-rabbit second 
antibody (200 pl/well) (make up ABC solution 30 min. before this step ends).
10. Wash 3 times with PBS.
11. Perforai ABC incubation by adding 100 pi of ABC solution to wells. Leave for 
30 min.
12. Wash once with PBS.
13. Visualize immunoreactivity in each well in turn by adding 100 pi DAB solution. 
Examine regularly for maximal staining intensity using light phase microscopy.
14. Wash 3 times with PBS and store in PBS.
15. Dehydrate in alcohol and Histoclear and then fix using Histofix.
At least 100 cells at a times 400 magnification were counted in 4 separate fields/well. 
A field was designated an area of the well in which the cell population did not overlap 
with a previously examined area. 3 different wells over 3 different culture 
preparations were examined using a phase contrast microscope (Nikon).
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2.6. Cell treatment.
Cortical neuronal cultures prepared from embryonic tissue are not susceptible to 
NMD A mediated excitotoxicity until about 12 days in vitro due to a number of 
factors. These factors are lack of receptor expression (Frandsen & Schousboe, 1990; 
Brian et al., 1991, Lustig et al., 1992; Weller et al., 1993; Akaneya et al., 1994; 
Griffiths et al., 1997; Cho et al., 2000; Hewett et al., 2000; Rudolph et al., 2000 & 
Skaper et al. 2001), lack of maturation of 2nd messenger systems (Keilhoff & Erdo, 
1991; Gai & Erdo, 1992), expression of neuroD (Katayama et al., 1997) and 
decreased oxidation state of the NMDA receptor (Sinor et al., 1997).
Experiments using NMDA as the excitotoxin were therefore perfonned on viable cell 
cultures between 12-16 days in vitro. However, when quinolinic acid was used to 
induce cell death, cultures older than 17 DIV were used as they become susceptible to 
this excitotoxin at this time point in vitro (Kim & Choi, 1987).
At the time in the project (June, 2001) when the effects of the adenosine A 2A receptor 
ligands on cortical neuronal viability were being looked at, only one report had 
examined the protective effect of any of the adenosine A2 A receptor ligands in vitro. 
Ferreira et al. (2001) demonstrated that it was necessary to incubate retinal neurons 
for 24 hr with COS 21680 before addition of 1 mM glutamate for the compound to 
exert neuroprotection via a metabolic effect. Therefore, it was decided initially to use 
this same incubation time period for the A2 A ligands before addition of excitotoxins. 
After addition of the A2 A ligands for 24 hr, excitotoxins were added for a further 48 hr 
before final cell death assessment.
2.7. Assessment of cell death.
Trypan blue uptake (Tennant, 1964) offers a quick and reliable method for measuring 
necrosis as cells succumbing to this form of cell death lose their membrane integrity, 
allowing uptake of the dye. Its use is established for measuring excitotoxic cell death 
(Mattson et al., 1995).
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These authors also reported that neurons adjacent to astrocytes are more resistant to 
excitotoxicity than neurons not in contact with these cells. This was also noted in the 
present study, so care was taken not to include neurons within a glial “pocket” in cell 
counts during assessment of cell death by this method. The cells were initially 
incubated with 0.4 % Trypan Blue solution (Sigma) for 10-15 min and then fixed in 4 
% formaldehyde for 25-30 min. Wells were then visualized under light microscopy 
at a magnification of times 400 (Nikon). Cells which failed to exclude trypan blue 
were scored as necrotic. The number of necrotic cells in 4 fields was counted 
(minimum 100 cells/field) and % necrotic cell death/well calculated as follows:-
%field 1 + %field 2 + %field 3 + %field 4 
% necrotic cell death/well = — --------------------------------------------
2.8. Statistical analysis.
See section 3.6..
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3. Methods for investigating the effects of glutamate and adenosine receptor 
ligands on bone cell cultures.
3.1. Cell culture.
Murine calvaiia derived MC3T3-E1 osteoblast-like cells were used in the present 
study. They were a generous gift from Professor Tim Skerry, Royal Veterinary 
College, London. A 75 cm^ flask of the cells (passage 7) was received in alpha- 
minimum essential medium (ct-MEM, Gibco) containing 20 % ECS (Gibco) 
supplemented with 100 lU/ml penicillin and 100 pg/ml streptomycin (P/S).
3.1.1. Freezing down ofMC3T3-El cells.
The cells were allowed to obtain full confluence and then frozen at -70°C so that 
aliquots of the cells would be available for future experiments. The following 
procedure was followed (aseptic):-
Cell cultures (one flask) were trypsinized by removal of the culture medium and 
adding just sufficient 0.5 % trypsin in MEM (Gibco, preheated to 37°C) to cover the 
cells. This was 10 ml. for a 75 cm^ flask and 5 ml for a 25 cm^ flask. The flask was 
then returned to the incubator and checked every 5 min for signs of cell detachment. 
When it was clear that the majority of the cells had detached, the flask was flooded 
with MEM (supplemented with 20% PCS) and all the contents pipetted in to a 15 ml 
centrifuge tube, ensuring all the detached cells were removed. They were then 
washed by initially centrifuging gently (3 mins at 500g) and resuspended in 5 ml a- 
MEM (with 20 % ECS and P/S). The washing process was repeated and the cells 
resuspended in 5 ml MEM. The cells were then counted in the same way that cortical 
neuron concentration was calculated and then the number adjusted by adding a-MEM 
(supplemented with 20% ECS + P/S) to give a concentration of 500,000/ml. A third 
of the cells were then reseeded in 25 ml culture medium (a-MEM with 20% ECS and 
P/S) in a 75 cm^ flask and returned to the incubator for later experiments.
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The remaining two thirds of the cells were then frozen for later use in case cells were 
lost due to contamination and they had to be resumected. The freezing process was 
achieved by transferring to culture medium containing 10 % DMSO. The 
DMSO/cells/medium mixture was then dispensed into 1 ml aliquots in ampoules and 
cooled at 4°C for 30 min. The cells were then slowly frozen by putting in a 
styrofoam box, first in a -20 °C freezer for 30 min and then in a -80°C freezer for 
storage.
3.1.2. Subculturing o f cells.
Subcultures were obtained every 5-7 days by removing the cells from the flask by 
trypsinization, washing, resuspension and counting as detailed above. 
Approximately one third of the cells were reseeded in a 75 ml flask in 25 ml a-MEM 
with 10 % ECS (changed every 2-3 days) and maintained at 31°C in a humidified 
atmosphere of 5 % C02-95 % air. The rest of the cells were seeded using a mixing 
needle (1 drop/well) in a-MEM (supp.with 10% ECS and P/S) in 96 well plates. 
Seeding density varied according to the experimental assay to be performed later (see 
below). After 24 hours the plated cells were switched to media supplemented with 50 
p,g/ml ascorbate and 5 mM p-glycerol phosphate and P/S. These supplements were 
added to the media as they accelerate the proliferation and differentiation of these 
cells (Harada et al., 1991; Quarles et al., 1992). In particular, it is known that 
glutamate release parallels alkaline phosphatase expression (a marker of 
differentiation, Bhangu et al., 2001). Since one of the main aims of the project was 
to assess the role of this transmitter in osteoblastic cell development and death, these 
supplements were required so that the cells expressed a maximal glutamatergic 
phenotype at the time of treatment.
3.1.3. Resurrection o f frozen cells.
This was achieved by gently thawing the previously frozen DMSO/cells/medium 
mixture by heating the end of a tube in a water bath. On thawing, the mixture was 
immediately pipetted into a 15 ml centrifuge tube.
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The storage tube was rinsed once with 5 ml a-MEM (with 20 % PCS and P/S) to 
ensure all of the cells were passed into the centrifuge tube. The cells were then 
washed once by initially centrifuging at 500g for 5 mins., aspirating the medium only 
and then resuspending the pellet in 10 ml medium. The entire cell suspension was 
then transfened to a 75 cm^ flask. To ensure that all the cells were transfeiTed to the 
flask, the centrifuge tube was then flooded with 10 ml a-MEM (with 20 % PCS and 
P/S). This flooding procedure was repeated and so the cells were seeded in 30 ml. of 
media. Half the media in the flasks was replaced after 24 hr and then every 2-3 days 
until subculturing.
3.2. Mitogenic activity assay.
Alamar Blue (Biosource) was used to assess cell viability. The active ingredient in 
this colorimetric assay is 7-hydroxy-3H-phenoxazin-3-one-10-oxide (resazurin, 
O’Brien et al., 2000). The dye relies on the principal that the internal environment of 
the proliferating cell is more reduced than that of non-proliferating cells. As the 
ratios of nicotine adenine dinucleotide phosphohydrogenase (NADPH)/nicotine 
adenine dinucleotide phosphate (NADP), flavin adenine dinucleotide hydrogenase 
(FADH)/ flavin adenine dinucleotide (FAD), flavin mononucleotide hydrogenase 
FMNH and nicotine adenine dinucleotide hydrogenase (NADH) increase during 
proliferation, Alamar Blue can be reduced by all of these intermediates which is 
accompanied by a measurable shift in colour (Nociari et ah, 1998).
Furthermore, as this dye can be reduced by cytochromes whereas tétrazolium salts 
cannot (O’Brien et ah, 2000), it offers increased sensitivity over these assays. The 
optimum incubation time for Alamai’ Blue when used with MC3T3-E1 cells was 
deteimined. This was found to be 4 hr when the cells were plated between 5,000/mh 
and 20,000/mh
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The general protocol for measuring cell viability in MC3T3-E1 cells was as follows:-
1. The old media was aspirated and fresh media (200 pi) added to test wells in 96 
well plates
2. 20 pi of Alamar Blue was added to each test well.
3. The plate was then returned to the incubator for 4 hr
4. The absorbance (A) was measured at 540 nm (lower wavelength, LW) and then 
595 nm (higher wavelength, HW) using a spectrophotometric plate reader (Dynex, 
USA)
5. The absorbance of 220 pi of media only was then measured at the same 
wavelengths mentioned in step 4.
6. The absorbance values of media only (step 5) were substracted from the 
absorbance values of Alamai* Blue and media (step 4) at both wavelengths to give 
the absorbance of the oxidized form of Alamar Blue in media -  absorbance of 
media only. The absorbance of the oxidized form at lower wavelength was called 
A O lw and absorbance of oxidized form at higher wavelength was called A O hw.
7. The correction factor; R q . (R o =  A O lw/A O hw) was then calculated.
8. The percentage of reduced Alamar Blue, AR was then calculated. AR = A lw(A hw 
X Ro) X 100)
To assess the effects of various compounds on MC3T3-E1 proliferation, cells were 
seeded at a density of 5,000/ml. Medium was changed to ascorbate and p-glycerol 
phosphate media (“switch”) media (with 10 % PCS) after 24 hr. At 6 days in vitro 
an initial cell viability assay according to the manufacturers instructions (above) was 
peifoi*med with Alamar Blue (Biosource). Agents were then added and cell viability 
assessed again at the desired time point after agent addition. Cell proliferation was 
expressed as the percentage of the pretreatment level.
3.3. Assay for alkaline phosphatase (ALP) activity.
To assess the effect of the agents on MC3T3-E1 ALP activity, the protocol of Suzuki 
et al. (1998), who examined the effects of epinephrine on expression of this enzyme in 
these cells was followed.
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Furthermore, as cell lines can show phenotypic drift after multiple passages and it is 
possible that the phenotype can differ between different laboratories, it was necessary 
to ensure the cells were characterised as regards their development. This was 
achieved by ensuring they differentiated in the same way as has previously been 
reported by assaying for alkaline phosphatase. Cells were plated at a density of 
5,000/ml. They were then switched to, and maintained in, ascorbate and P-glycerol 
phosphate (with 10% FCS and P/S) containing media for 11 days, after which time 
they were switched to the same media containing just 1% FCS for 24 hr Agents were 
then added for 48 hr For the initial cell characterization, the cells were fixed at 11 
DIV.
ALP activity in 96 well plates (adapted from Boyan (1989) & Lowry (1956)) was 
assessed as follows. Initially, the cells were fixed in 96 well plates. After washing 
twice in PBS, 100 pi of 0.05 % Triton (Sigma) was added to each well.
The 96 well plates were then frozen by putting them in a -70°C freezer and then 
having them thawed by placing in a water bath at 37°C. The mixture was then 
triturated carefully, ensuring no air bubbles were introduced as experience showed 
these can give erroneous readings during spectrophotometry. This freeze-thaw- 
titration process was then repeated.
100 pi ice cold 16 mM p-nitrophenylphosphate (BDH) in 2-amino-2-methyl-l- 
propanol (AMP) buffer (Sigma) was then added to each well. The plates were then 
incubated in a water bath at 37°C for 60 min and then read at 410 nm using a plate 
reader.
ALP catalyses the conversion of p-nitrophenylphosphate (colourless) to free 
nitrophenol (yellow) which in alkaline solution has strong absorption at a wavelength 
(410 nm) at which the substrate has little or no absorption (Lowry, 1956).
ALP
p-nitrophenyl phosphate + H2O -A p-nitrophenyl + P,
'%■
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3.4. Cell death assessment.
3.4.1. Necrosis.
Necrotic cell death in MC3T3-E1 cells was assessed using trypan blue uptake (see 
neuronal cultures (section 2.7)).
3.4.2. Apoptosis.
Cells were seeded at a density of 15,000/ml. in a 96 well plate in a-MEM with 20 % 
FCS and P/S. 24 hr later the medium was switched to ascorbate and p-glycerol 
phosphate containing media. At 3 days m vitro, the cells were washed 3 times with 
a-MEM with 0.5 % BSA and then exposed to the test compounds in a-MEM with 0.5 
% BSA. Caspase-3 activity was measured by immunostaining 18 hr later, a time 
point when apoptosis occurs in response to serum withdrawal in MC3T3-E1 cells 
(Jilka et al., 1998) and when expression of the protease is maximal (Chae et al., 2000).
3.4.3. Immunocytochemical method fo r  assessment o f caspase-3 expression.
Reagents used (unless stated otherwise, 200 pi of each reagent was used).
4 % Paraformaldehyde in PBS.
0.75 ml 36 % paraformaldehyde solution + 6 ml 0.1 M PBS.
0.2 % Triton in PBS.
8 pi triton in 4 ml PBS.
Blocking buffer.
5 ml PBS + 5 pi Tween 20 + 250 pi goat serum.
Anti-active caspase-3 antibody (Primary antibody. 1: 320 dilution).
Add a 5 pi aliquot of the antibody to 1600 pi blocking buffer = 50 pi added to each 
well if for 32 wells.
Secondary antibody (1:200 diln.l
600 pi GS & 15 pi stock secondary antibody + 2.385 ml PBS.
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ABC (avidin-biotin- peroxidase comvlex) solution (Vector, U.K.).
One drop A (avidin BH) & one drop B (biotinyiated horse radish peroxidase) added to 
2.5 ml PBS (left for 30 min at room temperature.)
DAB (di-azo-aminobenzene) solution (Vector. U.K.).
To 5 ml distilled water, 2 drops of buffer stock solution were added. The entire 
solution was then mixed well. 4 drops of DAB stock solution were then added and 
the entire solution mixed well again. 2 drops of hydrogen peroxide solution were 
then added and the entire solution mixed well. Finally, 2 drops of nickel stock 
solution were added and the entire solution mixed well.
Unless stated otherwise the volume added to each well was 200 pi.
1. Fix cells by incubating in 4 % paiaformaldehyde at room temperature for 25-30 
min Wash 3 times in PBS and then proceed to immunostaining.
2. Permeabilize fixed cells by incubating in 0.2 % Triton X-100 in PBS for 5 min at 
room temperature.
3. Wash 3 times in PBS.
4. Drain plus add 100 pi of blocking buffer and incubate for 2 hr at room temperature 
in a humidified chamber.
5. Wash once with PBS.
6. Add 50 pi of anti-active caspase 3 antibody in blocking buffer and incubate 
overnight in a humidified chamber at 4°C.
7. The following day, wash twice in PBS for 10 min, twice in PBS/0.1% Tween 20 
for 10 min and again twice in PBS for 10 mins. at room temperature.
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8. Drain and add 100 pi of the secondary antibody in blocking buffer. Incubate for 2 
hr at room temperature in a humidified chamber. Make up ABC soln. 30 mins. 
before this step ends.
9. Wash twice in PBS for 5 mins., once in PBS/0.1% Tween 20 for 5 min and once 
again in PBS for 5 min
10. Wash 3 times in PBS.
11. Perform ABC incubation by adding 100 pi of ABC solution to wells. Leave for 
30 min.
12. Wash once with PBS.
13. Visualize immunoreactivity in each well in turn by adding 100 pi DAB solution 
and examining regularly for maximal staining intensity using light phase microscopy.
14. Wash in PBS 3 times and take photos if necessary.
The number of cells positively staining for caspase-3 was quantified by using phase 
contrast light microscopy in the same way that counts for trypan blue positive stained 
cells were performed in assessing cell death of cortical neurons as mentioned earlier 
(section 2.7. ).
3.5. Drugs.
All drugs were obtained from Sigma, Dorset, U.K. except 2-amino-5- 
phosphonopentanoic acid (AP5) and 2-p-(2-carboxyethyl)phenethylamino-5’-/V- 
ethylcarboxyamidoadenosine hydrochloride (CGS 21680) (Tocris, Bristol, U.K. ). 4- 
(2-[7-amino-2-[2rfuryl][l,2,4]triazolo[2,3-a][l,3,5]triazo-5-yl-amino]ethyl)phenol 
(ZM 241385) was obtained from Zeneca, Macclesfield, U.K.
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3.6. Statistical analysis.
Results are expressed as the mean ± S.E.M. (standard eiTor of the mean) of the stated 
number (n) of wells. When the basal or control expression level is shown 
graphically, it is the same value as that induced by 0 pM of an agent. The statistical 
significance of any difference was assessed by either the unpaired t-test or one way 
analysis of variance (ANOVA) with a post test of Student-Newman-Keuls multiple 
comparisons test (SNK test). Differences were considered significant when p < 0.05 
unless stated otherwise.
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4. The effects of glutamate and adenosine receptor ligands on neuronal cultures.
4.1. Development of cortical and hippocampal neurons in culture.
As assessed by light phase microscopy, 3 hr after plating, neurons, recognised by their 
spherical shape, already showed process development, marked by neuritic extension. 
After 24 hr in vitro, cells began to aggregate and differentiate into morphological 
subtypes. After 72 hr a neuritic network between adjacent cell aggregates started to 
form. Between 72 hr and 14 days in vitro, this neuritic extension continued with a 
corresponding increase in neuron size and complexity of processes. At the time of 
experiments (12-16 DIV), viable neurons were distinctly recognisable by having 
bright oval somata (Kuiiyama & Ohkuma, 1990; Mattson et al., 1995) with extensive 
neuritic ai’borisation between adjacent cell aggregates. Pyramidal neurons, 
recognised by their triangular soma, stout apical dendrite and smaller diameter basilar 
dendrites (Buchhalter & Dichter, 1992) were evident. Non-pyramidal, stellate 
neurons were also present (Figure 2a. p. 61). The overall morphological development 
of the cultures was similar to those observed by others (Kuriyama & Ohkuma, 1979; 
Buchhalter & Dichter, 1992; Mattson et al., 1995).
4J.1. Cell characterization.
Immunostaining against neurofilament (NF-200) revealed that the cultures consisted 
of an homogeneous neuronal population of about 90 % of this cell type (Figure 2b, 
p.62). Staining against GFAP showed that the remainder of the cell population 
consisted of astrocytes. Most of the non-neuronal cell population (about 8 %) of this 
cell type were protoplasmic, recognised by having processes which were variable in 
shape and which closely followed the contours of adjacent cells. There was also some 
contamination (about 2 %) by fibrous astrocytes, recognised by their smaller size and 
finger-like processes (Juurlink & Hertz, 1995). Contamination by astrocytes was 
restricted to “pockets” which tended to appear around the edges of the wells. Staining 
against integrin ocM for microglial detection and 0 4  for oligodendrocytes showed 
there was negligible (< 0.1 %) contamination in the cultures from these cell types.
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»Figure 2a. Anti-neuroniament immunostained hippocampal neuronal cultures.
Hippocampal neuronal cultures at 14 DIV were fixed and immunostained against the 
200 kD intermediate filament (1:500 dilution). Pyramidal cells (arrow on right), 
recogniseable by their triangular soma, stout apical dendrite and smaller basilar 
dendrites can be seen as well as non-pyramidal, stellate neurons (arrow on left). Bar 
= 40 pM.
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Figure 2b. Anti glial fibrillary acidic protein (GFAP) stained hippocampal 
cultures. Hippocampal cultures were fixed at 14 DIV and immunostained against 
GFAP (1:500 dilution). This pocket of glial contamination contains mostly type-1 
astrocytes.
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4.2. Effect of NMDA on cortical neuron cultures.
Figures 3 and 4 show NMDA induced concentration-dependent cell death in cortical 
neuronal cultures. After 24 hr, there was no evidence of neuronal damage by 
NMDA. However, after 48 hr, 30 pM NMDA non-significantly increased neuronal 
cell death from a basal level of 9+2.5 % (n=13) to 22+5 %. At a concentration of 100 
pM, NMDA significantly increased cell death to 31±4 % (p<0.001 vs. basal cell 
death level, n=17, SNK test) Viable neurons with round oval somata and extensive 
neuritic arborization displayed distinct somatic swelling/vacuolization and neuritic 
fragmentation on exposure to the excitotoxin (Figures 5b & 6. p. 67 & 68). Their cell 
bodies also stained positive with trypan blue.
4.2.1. Effect o f 2-amino-5-phosphonopentanoic acid (AP5) on cell death induced by 
NMDA.
Addition of the NMDA selective antagonist, DL-2-aminophosphonopentanoic acid, 
(AP5) (Evans et al., 1982) afforded protection against NMDA-elicited cell damage 
Figs. 3 & 4). AP5 non-significantly reduced 30 pM NMDA-induced cell death from 
22±5 % to 8±2 % (n=8) but significantly attenuated cell death induced by 100 pM 
NMDA from 31 ±4 % to 7.5±2 % (p<0.01, n=13, SNK test).
4.3. Effect of kynurenines on cortical neuronal cultures.
Quinolinic acid non-significantly increased cell death in cortical neuronal cultures 
(Figure 7. n=3). Cell damage induced by quinolinic acid was morphologically similar 
to that induced by NMDA, in that the cells showed somatic swelling/vacuolisation 
and neuritic fragmentation. They also took up trypan blue. The broad spectrum 
glutamate receptor antagonist, kynurenic acid (Stone & Burton, 1988) had no effect 
on the response to quinolinic acid (n=2).
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Figure 3. Effect of CGS 21680 (CGS) and AP5 on cortical neuronal cultures. 
At 12-16 DIV, cells were incubated with CGS 21680 for 24 hr. NMDA was then 
added and cell death was assessed an additional 48 hr after NMDA addition 
by trypan blue exclusion (n=4).
a. p<0.001 vs. 0 pM & 10 pM NMDA (n=7, SNK test).
b. p<0.01 vs. 100 pM NMDA (n=17, SNK test).
F=7.941.
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Figure 4. Effect of ZM 241385 (ZM) and AP5 on cortical neuronal cultures.
At 12-16 DIV, cells were incubated with ZM 241385 for 24 hr. NMDA was then 
added and cell death was assessed an additional 48 hr after NMDA addition by 
trypan blue exclusion (minimum n=4).
a. p<0.001 vs. 0 pM & 10 pM NMDA (n=7, SNK test).
b. p<0.001 vs. 100 pM NMDA (n=17, SNK test).
c. 0.05 pM ZM: p<0.001 vs. 100 pM NMDA (n=13, SNK test).
d. 5 pM ZM: p<0.01 vs. 100 pM NMDA (n=11,SNK test). 
F=7.724.
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Figure 5a. Untreated cortical neuronal cultures at 14 DIV. Viable neurons at this 
stage in culture are recognised by having compact, oval somata linked by extensive 
neuritic arborisation.
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Figure 5b. Effect of 30 pM NMDA on cortical neuronal cultures. Somatic 
swelling/vacuolisation as a morphological hallmark of excitotoxicity in vitro can be 
seen (arrows). Bar = 40 pM.
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Figure 6. Effect of 100 |iM NMDA on cortical neuronal cultures. The
morphological hallmarks of excitotoxicity m vitro, namely somatic 
swelling/vacuolisation and neuritic fragmentation are more marked when cells are 
exposed to this higher concentration of NMDA (arrows). Bar = 40 p,M.
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Figure 7. Effect of quinolinic acid (QA) and kynurenic acid (kyn. acid) on cortical 
neuronal cultures. At 17-21 DIV, cells were incubated with kynurenic acid for 24 
hr. QA was then added and cell death was assessed an additional 48 hr after QA 
addition by trypan blue exclusion (n=3 for QA data and n=2 for QA+kyn. acid data).
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4.4. Effect of CGS 21680 on cortical neuronal cultures.
As can be seen in Figure 3. 0,02 jiM CGS 21680 had no effect on the basal level of 
cell death but non-significantly reduced the level of cell death induced by 10 jbiM 
NMDA from 8.5±4 % (n=7) to 0.7±0.5 % (n=4) and reduced cell death induced by 30 
jiM NMDA from 22±5 % to 4±3 % (n=4). However, CGS 21680 did not affect cell 
death induced by 100 |iM NMDA.
At 0.05 jiM, CGS 21680 did not attenuate cell death induced by NMDA. As the 
concentration was increased to 0.5 jiM and then 5 |iM, there was a non-significant 
trend that the agent decreases neuronal damage. This was to the extent that at 5 |iM, 
the compound was able to non-significantly reduce cell death evoked by 30 jiM 
NMDA to 8.5±2 % (n=5). However, 5 |liM  CGS 21680 did not protect against cell 
death elicited by 100 fxM NMDA.
4.5. Effect of ZM 241385 on cortical neuronal cultures.
0.05 pM and 5 pM ZM 241385 had no effect on cell death induced by 10 pM NMDA 
or 30 pM NMDA (Figure 41. 0.05 pM significantly reduced cell death induced by
100 pM NMDA from 32±4 % to 14±2 % (p<0.001, n = ll, SNK test) and 
5 pM ZM 241385 significantly reduced cell death induced by 100 pM NMDA to 
12±2 % (p<0.01, n=4, SNK test).
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Figure 8. Effect of NMDA on hippocampal neuronal cultures. At 12-16 DIV, 
cells were exposed to NMDA and cell death assessed by trypan blue uptake 
an additional 48 hr after NMDA addition (n=4).
a. p<0.05 vs. 0 |iM NMDA (n=4, SNK test).
b. p<0.001 vs. 0 pM & p<0.05 vs. 30 pM NMDA (n=4, SNK test).
c. p<0.001 vs. 0 pM, p<0.01 vs. 30 pM & p<0.05 vs. 100 pM NMDA 
(n=4, SNK test).
F=21.931.
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Figure 9. Effect of NMDA on hippocampal neuronal viability as assessed 
by MTS reduction. Cultures were incubated with NMDA and cell viability assessed 
an additional 48 hr after NMDA addition (n=3).
a. p<0.0001 (two-tailed value) vs. 0 pM.
(unpaired t-test, n=3).
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4.6. Effect of NMDA on hippocampal neuronal cultures.
Figure 8 reveals that NMDA induced concentration-dependent cell death in 
hippocampal cultures as assessed by trypan blue uptake. 30 pM NMDA significantly 
increased cell death from a basal level of 9.5±3 % to 34±8 % (p<0.05, n=4, SNK test).
100 pM of the agent significantly increased cell death to 54±8 % (p<0.05 vs. 0 pM, 
n=4, SNK test). IniM NMDA significantly increased neuronal death to 74±2 %
(p<0.01 vs. 0 pM and 30 pM NMDA, n=4). As assessed by light phase microscopy, 
cell death in these cultures was morphologically identical to cell death in cortical 4v
neuronal cultures with NMDA causing distinct somatic swelling/vacuolisation and 
neuritic fragmentation to hippocampal neurons.
However, as assessed by MTS reduction, ImM NMDA caused a significant increase 
in neuronal viability or cell number to 141±3 % (p<0.0001 (two-tailed value, n=3, 
unpaired t-test)) of basal levels after 48 hr (Figure 9). 4
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5. The effects of glutamate and adenosine receptor ligands on bone cell cultures.
5.1. Characterisation of MC3T3-E1 cells.
■ J K
MC3T3-E1 cells cultured in ascorbate and (3-glycerol phosphate supplemented fi■f
(“switch”) media showed a significantly higher ALP activity (0.4+0.02 U/ml, n=8) 
compared to cells cultured in medium without these supplements (“normal”) which 
showed an ALP activity of 0.26+0.01 U/ml (p<0.01, unpaired t-test, n=8). 
Morphologically, cells maintained in switch medium showed a more cuboidal 
appearance compared to cells maintained in noimal medium which appeared 
mesenchymal.
5.2. Effect of N-methyl-D-aspartate (NMDA) on MC3T3-E1 cell development.
5.2. Ejfect o f NMDA on MC3T3-E1 cell proliferation.
5.2.1. 24 hr exposure.
None of the concentrations of NMDA had a significant effect on MC3T3-E1 
proliferation after 24 hr (Figure 10). However, after 48 hr, 300 |iM NMDA 
significantly increased MC3T3-E1 cell viability from a basal level of 104+2 % to 
127+2 % (p<0.001, n=4, SNK test). After 72 hrs., 300 pM NMDA had significantly 
increased viability to 112+2 % (p<0.05 vs. basal cell viability level, n=4, SNK test).
However, 1000 pM NMDA did not have any significant effect on cell viability levels 
after 48 or 72 hr and had no effect on moiphology of MC3T3-E1 cells as assessed by 
light phase microscopy.
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Figure 10. Effect of N-methyl-D-aspartate (NMDA) on MC3T3-E1 cell viability.
At 6 DIV, cells were subject to a pretreatment viability assay and then treated with 
NMDA. Cell viability was assessed after an additional 24, 48 & 72 hr after NMDA 
addition (n=4).
a. p<0.001 vs. basal cell viability level (n=4, SNK test).
b. 72 hr. p<0.05 vs. basal cell viability level (n=4, SNK test).
F=20.370.
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Figure 11. Effect of NMDA and on MC3T3-E1 cell viability. At 6 DIV,
cells were subjected to a pretreatment viability assay and then incubated 
with the agents. Cell viability was assessed after an additional 72 hr after 
NMDA & H A  addition (n=6).
a. p<0.001 vs. all other treatments (n=6, SNK test).
F=144.67.
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Figure 12. Effect of NMDA on MC3T3-E1 cell differentiation. At 11 DIV, 
maintenance medium was switched to medium containing 1 % PCS for 24 hr. 
Agents were then added and cell differentiation was assessed after an additional 
48 hr by assaying for alkaline phosphatase (n=4).
a. p< 0.05 vs. basal expression level (n=4, SNK test).
b. p<0.05 vs. basal expression level (n=4, SNK test).
c. p<0.05 vs. basal expression level (n=4, SNK test).
d. p<0.05 vs. 1000 pM NMDA (n=4, SNK test). 
F=4.348.
77
5.2.1.2. 72 hour exposure.
NMDA did not have a significant mitogenic effect when exposed to MC3T3-E1 cells 
for 72 hr (Figure 11)
5.2.2. Ejfect o f NMDA on MC3T3-E1 cell differentiation.
NMDA at 100 pM significantly increased alkaline phosphatase expression from a 
basal level of 4.8+0.2 U/ml to 6.1+0.2 U/ml (p<0.05, n=4, SNK test) an effect non- 
significantly reduced by the NMDA selective antagonist, AP5 (100 pM) to 5.4+0.2 
U/ml (p<0.05, n=4, Figure 12). 300 pM NMDA significantly increased alkaline
phosphatase expression to 6±0.1 U/ml (p<0.05 vs. basal levels, n=4, SNK test) an 
effect again non-significantly reduced by AP5. 1000 pM NMDA significantly 
increased alkaline phosphatase expression to 6.3+0.5 U/ml (p<0.05 vs. basal levels, 
n=4, SNK test), an effect significantly reduced by AP5 to 4.73 U/ml (p<0.05, n=4, 
SNK test). No difference in morphology was observed between untreated and treated 
cells.
5.3. Effect of QA on MC3T3-E1 cell development.
5.3.1. Ejfect o f QA on MC3T3-E1 cell proliferation.
5.3.1.1. 24 hour exposure.
After 24 hr, quinolinic acid (300 & 1000 pM) had no significant effect on MC3T3-E1 
viability (Figure 13). However, 3000 pM QA significantly increased cell viability to 
158+7 % of that of basal levels (p<0.05, n=4, SNK test). After 48 hr, 3000 pM QA 
caused a significant increase in cell viability to 167+10 % of basal levels (p<0.05, 
n=4, SNK test). After 72 hr, 300 and 1000 pM quinolinic acid were able to induce a 
non-significant tendency to increase cell viability. 3000 pM QA significantly 
increased cell viability to 165+14 % of basal levels (p<0.05, n=4, SNK test).
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Figure 13. Effect of quinolinic acid (QA) on MC3T3-E1 cell viability. At 6 DIV, 
cells were subjected to a pretreatment cell viability assay and then exposed to 
quinolinic acid for 24 hr. Cell viability was assessed after an additional 24, 48 & 
72 hr after QA addition (n=3).
a. 24 hr: p<0.05 vs. 0 pM, 300 pM and 1000 pM QA (n=3, SNK test).
b. 48 hr: p<0.05 vs. 0 pM, 300 pM and 1000 pM QA (n=3, SNK test).
c. 72 hr: p<0.05 vs. 0 pM and 300 pM (n=3, SNK test).
F=9.184.
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Figure 14. Effect of quinolinic acid (QA) and HgOg on MC3T3-E1 cell viability.
At 6 DIV, cells were subject to a pretreatment viability assay and then exposed 
to the agents. Cell viability was assessed an additional 72 hr after QA &
addition (n=6).
a. p<0.001 vs. all other treatments (n=6, SNK test).
F=143.82.
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Figure 15. Effect of quinolinic acid (QA) on MC3T3-E1 differentiation.
At 11 DIV, cells were switched to maintenance media containing 1% PCS 
for 24 hr. Agents were then added and differentiation was assessed an 
additional 48 hr after QA & AP5 addition by assaying for alkaline 
phosphatase (n=4).
a. p<0.05 vs. 0 pM (n=4, SNK te s t).
b. p<0.01 vs. 1000 pM QA (n=4, SNK test).
c. 3000 pM QA: p< 0.01 vs. 1000 pM QA and p<0.05 vs. 300 pM QA 
n=4, SNK test).
F=6.104.
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5.3.1.2. 72 hour exposure.
It can be seen in Figure 14, that quinolinic acid did not have a significant mitogenic 
effect when exposed to MC3T3-E1 cells for 72 hr.
5.3.2. Ejfect o f quinolinic acid on MC3T3-E1 cell differentiation.
At 300 pM , quinolinic acid (QA) non-significantly increased alkaline phosphatase 
expression, an effect which AP5 (100 pM ) non-significantly reduced. 1000 p M  QA 
significantly increased alkaline phosphatase expression to 6.7±0.1 U/ml from a basal 
expression level of 5.2+0.9 U/ml (p<0,05, n=4, SNK test, Figure 15). an effect 
reduced by AP5 to 4.7+1 U/ml (p<0.05, n=4, SNK test). 3000 p M  QA had no effect 
on alkaline phosphatase expression relative to basal levels. In fact, this concentration 
of QA was able to significantly reduce alkaline phosphatase expression to 5±1 U/ml 
This was significantly different from 1000 p M  QA (p<0.01, n=4, SNK test) and 300 
p M  QA (p<0.05, n=4, SNK test), and was not attenuated by AP5, No morphological 
difference was observed between treated and control cells.
5.4. Effect of adenosine A%A receptor ligands on MC3T3-E1 cell development.
5.4.1. Ejfect o f adenosine Â2a receptor ligands on MC3T3-E1 proliferation.
CGS 21680 (0.001, 0.01 & 0.1 p M ) non-significantly caused a concentration- 
dependent increase in cell viability (Figure 16).
At concentrations of 0.001 and 0.01 p M , Z M  241385 also non-significantly increased 
cell viability. At 0.1 pM , Z M  241385 significantly increased cell viability to 191+14 
% of basal levels (p<0.05, n=6, SNK test).
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Figure 16. Effect of CGS 21680 (CGS) and ZM 241385 (ZM) on MC3T3-E1 
cell viability. At 6 DIV, cells were subject to a pretreatment viability assay and 
then exposed to either CGS 21680 alone, ZM 241385 alone or the agonist 
combined with the antagonist. Cell viability was assessed 72 hr after CGS & 
ZM addition (minimum n=6).
a. 0.1 |iM ZM: p<0.05 vs. 0 pM ZM (n=6, SNK test).
F=4.374.
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Figure 17. Effect of CGS 21680 (CGS) and ZM 241385 (ZM) on 
differentiation of MC3T3-E1 cells. Cells were treated as described 
in methods. At 11 DIV the cells were switched to maintenance media 
containing 1 % PCS for 24 hr. Agents were then added and cell 
differentiation assessed by assaying for alkaline phosphatase an 
additional 48 hr after CGS & ZM addition (n=4).
a. p<0.05 vs. 0.001 pM CGS (SNK test, n=4).
F=3.529.
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Figure 18. Effect of hydrogen peroxide ( H A )  ori MC3T3-E1 cell viability.
At 6 DIV, cells were subject to a pretreatment viability assay and then treated 
with hydrogen peroxide (HgOg). Cell viability was assessed an additional 72 hr
after H A^^Iclition (n=6).
a p <0.0001 (two-tailed value) vs. all other treatments (unpaired t-test, n=6). 
F=89.333.
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When combined with ZM 241385, 0.001 piM CGS 21680 non-significantly increased 
cell viability to 179+8 % of basal levels and 0.01 fxM CGS 21680 non-significantly 
increased cell viability to 195±13 % of basal.
5.4.2. Ejfect o f adenosine A 2a receptors on MC3T3-El differentiation.
CGS 21680 (0.001 jliM) non-significantly increased alkaline phosphatase expression 
from a basal level of 5+0.3 U/ml to 6.3+0.4 U/ml, an effect significantly reduced by 
0.01 [lU ZM 241385 to 4.9+0.2 U/ml (p<0.05, n=4, SNK test, Figure 17). 0.01 ^M 
CGS 21680 non-significantly increased alkaline phosphatase expression to 6.2+0.3 
U/ml. Neither of the agents induced any morphological changes as assessed by light 
phase microscopy.
5.5. Effect of nitrosative and oxidative stress on MC3T3-E1 cell viability.
S-nitroso-N-acetyl-penicillamine (SNAP) had no effect on MC3T3-E1 cell viability 
(data not shown) and hydrogen peroxide (H2 O2 ) at 10 jUiM & 100 pM was not 
significantly injurious to MC3T3-E1 cells (Figure 181. In fact, 10 pM H 2 O2  induced 
a non-significant increase in cell viability relative to control. However, 1000 pM 
H2 O2  dramatically significantly decreased cell viability from a basal level of 130±7 % 
to 12.7±3 % (p<0.001, n=6, SNK test). Morphologically, cell damage induced by 
H2 O2  was marked by swelling of the cytoplasm and lysis of the plasma membrane. 
Cell viability as assessed by trypan blue uptake showed a good conelation with that 
obtained by Alamar Blue reduction (data not shown).
Neither NMDA (Figure 11), quinolinic acid (Figure 14) or the adenosine A2 A 
receptor ligands had a significant effect on the response to hydrogen peroxide. 
However, 100 pM H2 O2  significantly reduced the proliferative effect of 0.1 pM CGS 
21680 alone (Figure 191 from 181111 % to 143111 % (p<0.01, n=6, SNK test) and 
significantly reduced the proliferative effect of 0.1 pM ZM 241385 from 191111 % to 
143111 % (p<0.01, n=6, SNK test, Figure20).
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Figure 19. Effect of and CGS 21680 (CGS) on MC3T3-E1 cell viability.
At 6 DIV, cells were subject to a pretreatment viability assay and then treated 
with CGS 21680 and various concentrations of hydrogen peroxide (H^Og).
Cell viability was assessed an additional 72 hr after CGS & addition (n=6).
a. p< O.OIvs. 0 pM CGS/no (n=6, SNK test).
b. p<0.01 vs. 0.1 pM CGS/no H^Og (n=6, SNK test).
c. p<0.001 vs. all other treatments (n=6, SNK test).
F=69.1.
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Figure 20. Effect of and ZM 241385 (ZM) on MC3T3-E1 cell viability.
At 6 DIV, cells were subject to a pretreatment viability assay and then exposed to 
ZM 241385 and various concentrations of hydrogen peroxide (H^Og). Cell viability
was assessed an additional 72 hr after ZM & addition (n=6).
a. p<0.01 vs. ZM/no (n=6, SNK test).
b. 0.1 pM ZM+100 pM HgOg: p<0.01 vs. 0.1 pM ZM/no H20g(n=6, SNK test).
0 . p<0.001 vs. all other treatments (n=6, SNK test).
F=32.106.
5.6. Effect of serum withdrawal on MC3T3-E1 cell apoptosis.
Serum withdrawal significantly increased the number of cells positively staining for 
caspase-3 expression to 10+1 % (p<0.05, n=4, SNK test, Figure 211 from a control 
level of 7±0.4 % (n=4). Cells positively staining for this protease also displayed 
distinct chromatin condensation and cell shrinkage as assessed by light phase 
microscopy. The A2 A receptor ligands, the selective Ai receptor agonist 
cyclopentyladenosine (CPA, 0.02 pM) and quinolinic acid (3000 pM) had no 
significant effect on expression of caspase-3.
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Figure 21. Effect of serum withdrawal on caspase-3 expression in MC3T3-E1 
cells. At 3 DIV, cells were washed 3 times in a-MEM containing 0.5 % bovine 
serum albumin. Caspase-3 activity was assessed by immunostaining 18 hr later 
as described in methods. CGS 21680 (CGS), ZM 241385 (ZM), 
cyclopentyladenosine (CPA) & quinolinic acid ((QA), (n=4)).
a. p<0.05 vs. serum control (n=4, SNK test).
F=4.594.
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6. Discussion of the effects of glutamate and adenosine receptor ligands on
neuronal cell cultures.
6.1. Discussion of the use of hippocampal vs. cortical neuronal cultures as in vitro 
models of excito toxicity.
Hippocampal neuronal cultures were more sensitive to NMDA than cortical neuronal 
cultures were, as has previously been reported (Rondouin et ah, 1988). The
number of papers in the literature reporting the use of these neuronal cultures for in I
vitro models of excitotoxicity is about equal and extensive for both cell types.
Several laboratories have examined why there is this difference in vulnerability to 
excitotoxicity and a number of factors appeal' to influence the susceptibility of a 
neuron to the phenomenon. These are glutamate receptor expression (Mattson &
Kater, 1988), maturation of the receptor complex (Peterson et al., 1989), maturation 
of 2nd messenger systems (Behrens et ah, 1996; Marks et ah, 2000) the oxidation 
state of the receptor (Sinor et ah, 1997), the presence of neuroD (Katayama et ah,
1997) or calretinin (Lukas & Jones, 1994) as well as the state of development of an 
inhibitory neurotransmitter system (e.g. GAB A) (Cai & Erdo, 1991).
In agreement with the literature, both cortical and hippocampal cultures did not
become susceptible to NMDA-mediated excitotoxicity until about 14 days in vitro. It 
is known that the NMDA receptor is developmentally regulated in both neuronal 
culture types (Frandsen & Schousboe, 1990; Drian et ah, 1991, Lustig et ah, 1992; 
Weller et ah, 1993; Akaneya et ah, 1994; Griffiths et ah, 1997; Gonzalez-Zulueta et 
ah, 1998; Cho et ah, 2000; Hewett et ah, 2000; Rudolph et ah, 2000; Sinor et ah, 
2000; Skaper et ah 2001). However, Peterson et ah (1989) revealed that glutamate 
binding to the NMDA receptor during development in vivo is greater in the 
hippocampus than it is in the cortex. Furthermore, Olverman et ah (1984) showed 
that the density of binding sites for [^H]-D-AP5 is greater in rat hippocampal 
membranes than it is in cortical membranes, suggesting that the number of functional 
NMDA receptors is higher in the hippocampus than it is in the cortex in vitro.
It is likely that this same level of receptor expression occurs in cultures of these brain 
areas and this would explain the increased vulnerability of hippocampal cultures over 
cortical cultures to excitotoxicity.
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In support of this, Kovacs et al. (2001) found that the expression of functional NMDA 
receptors was greater in vivo in the cortex relative to the striatum. This enhanced 
expression of NMDA receptors in cortical tissue was preserved in vitro and cortical 
neuronal cultures proved more sensitive to excitotoxicity than striatal neuronal 
cultures. However, it cannot be excluded that other factors apart from enhanced 
expression of NMDA receptors contributed to the increased sensitivity of 
hippocampal neuronal cultures over cortical neuronal cultures observed in the present 
project.
In the project, cortical neuronal cultures served as an adequate in vitro model for 
investigating neuroprotective mechanisms of action. Cortical neuronal cultures in 
general were easier to establish than hippocampal cultures. As the cortex is a much 
larger brain area than the hippocampus, the dissection procedure is a lot quicker and 
so the likelihood of establishing viable neuronal cultures using the cortex is much 
greater. Also, when the cortex is cultured, more experimental wells are yielded. 
Furthermore, experience showed that cortical neuronal cultures could be established 
when the cells were seeded in 96 well plates using just poly-D-lysine (10 pg/ml) 
without laminin as the substrate. This necessitated the cells to be seeded at a density 
of between 400,000 and 500,000 cells/ml which would not be possible using 
hippocampal tissue. As laminin is an expensive substrate, for economic reasons as 
well, cortical neurons are more advantageous to use than hippocampal neurons.
Despite the fact that hippocampal neurons are more more susceptible to excitotoxicity 
than cortical neurons, the advantages of the latter cell type for use in neuronal cell 
culture as an in vitro model of excitotoxicity outweigh the disadvantages. Thus, 
unless one has a specific reason for using hippocampal neuronal cultures, it is 
suggested that cortical neuronal cultures are a better choice to investigate the 
mechanism of action of neuroprotective agents than hippocampal neuronal cultures.
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6.2. Discussion of cell viability assays for quantification of excitotoxic cell death.
During the project, a number of assays were used to quantify excitotoxic cell death. 
Intially, a colorimetric assay, (3-(4,5-dimethylthiazol-2-yl)-5-(-3- 
carboxymethoxyphenyl)-2-(-4-sulfophenyl)-2H-tetrazolium inner salt; MTS) was 
used to determine cell viability. Recently, a number of assays based upon the 
reduction of tétrazolium salts have been promoted in the form of several commercial 
kits aimed at measuring “cell proliferation”. These methods rely on the concept that 
tétrazolium salts are readily reduced to their respective foiTnazans by metabolically 
active cells.
The general method for the use of these reagents is that the tétrazolium salt is added to 
microcultures of cells, incubated until the formazan product is produced (1-4 hrs. in 
the case of MTS). The contents of the well are then triturated to ensure an even 
distribution of this soluble formazan and the absorbance read in triplicate in a 96 well 
plate at 490 nm. According to the manufacturers (Promega), “MTS is bioreduced by 
cells into a coloured formazan product that is soluble in tissue culture medium”. 
Furthermore it is stated that the “quantity of formazan product as measured by the 
amount of 490 nm absorbance is directly proportional to the number of living cells in 
culture” (Promega technical bulletin No. 245, 1999). Thus, it was hoped that this 
colorimetric dye would offer a quick, convenient, non-subjective assay to quantify 
cell death. However, it was soon realized that a number of excitotoxins were not 
inducing concentration-dependent cell death as assessed by this method in cultures in 
the present study. Why this is the case is now discussed.
Major emphasis in the literature is put on the role of mitochondrial dehydrogenases 
and more specifically the role of succinic dehydrogenase and the mitochondrial 
electron carriers in the respiratory chain subsequent to ubiquinone when discussing 
the bioreduction of tétrazolium salts (Marshall et al., 1995). As reduction is 
frequently depicted as the addition of hydrogen, it is fundamentally due to the 
addition of electrons, the simultaneous transfer of protons is incidental.
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Indeed, tétrazolium salts are sometimes refeiTed to as artificial electron acceptors. 
Furthermore, the reaction whereby tétrazolium salts is reduced occurs via the 
formation of a free radical intermediate, tetrazolinyl in which only one electron has 
been transfeired to the tetrazole ring (Marshall et ah, 1995).
:r:
It is widely accepted that NMDA mediated excitotoxicity occurs in part via 
intracellular accumulation of superoxide free radicals (Lafon-Cazal et al., 1993; 
Reynolds & Hastings., 1995; Patel et al., 1996), that mitochondrial electron transport 
is enhanced during NMDA mediated cell death (Sengpiel et al., 1998) and that 
glutamate itself supports MTT reduction by isolated mitochondria (Liu et al., 1997). 
Thus it is possible that superoxide generation during cell death by these agents could 
cause the reduction of tétrazolium salts. Furtheimore, it should be noted that the 
reduction of nitroblue tétrazolium actually forms the basis of a well established 
indirect assay for superoxide dismutase (Marshall et ah, 1995). Also, although it has 
been observed by other investigators that MTT reduction may occur 
extramitochondrially (Berridge & Tan, 1993; Liu et al., 1997), superoxide free radical 
generation by excitotoxins could still affect this (Patel et al., 1996). Indeed, other 
authors have noted discrepancies between tétrazolium salt assays and other assays of 
cell viability (Uliasz & Hewett, 2000).
Therefore it is recommended that caution be exercised in the use of tétrazolium salts 
as indicators of excitotoxic cell death because although cell death may be occurring, 
cell viability as measured by formazan production may appear to be normal or even 
enhanced by excitotoxins.
It was therefore decided to use trypan blue exclusion (Tennant, 1964) to quantify cell 
death. The use of the dye in quantification of excitotoxic cell death is established 
(see Mattson et al., 1996). Although cheap, the use of this method as a marker of cell 
death has severe limitations, namely, it requires the use of cell counts which can be 
very time-consuming and tedious. Furthermore, assessment of cell death using cell 
counts can be subjective. Also, trypan blue exclusion suffices only as a marker of 
necrosis and will not quantify apoptotic cell death.
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Thus it was attempted to use a spectrophotometric method for trypan blue 
quantification of cell death (Uliasz & Hewett, 2000) in the hope that this would 
overcome the limitations of cell counts with the dye. However, this method was also 
found to be quite tedious as it necessitated cell lysis with sodium dodecyl sulphate and 
careful tituration of the lysate without introducing air bubbles. It also required an 
initial cell seeding density of at least 300,000 cells/ml. which could not be obtained 
with hippocampal neuronal cultures which were the culture type being used at that 
stage in the project.
Alamar Blue (Biosource) reduction was used to measure bone cell viability and was 
found to be a quick, reliable and sensitive colorimetric method. This dye was able to 
quantify hydrogen peroxide-induced injury in these cells which showed a good 
correlation with cell death quantification assessed by cell counts with trypan blue. 
Thus, it seems that this colorimetric method is not susceptible to interference by 
superoxide free radical production and would offer a quick reliable method for 
measuring excitotoxic cell death as well.
6.3. Discussion of effects of agents on cortical neuronal cultures.
6.3.1. Effect ofAPS on cortical neuronal cultures.
The aim of this project was to establish what the exact role of the adenosine A2A 
receptor is in neuronal viability. Using a well established in vitro model for 
examining the action of neuroprotective agents i.e. cortical neuronal cultures, AP5 
was able to attenuate NMDA elicited cell damage in the neuronal cultures in the 
present study, suggesting that cortical neuronal cultures were serving as a good in 
vitro model for excitotoxicity.
6.3.2. Effect o f kynurenines on cortical neuronal cultures.
Quinolinic acid showed a trend of eliciting cell death in cortical neuronal cultures 
(Figure 7), an observation compatible with the growing body of evidence that QA is 
an endogenous neurotoxin as its concentration is known to be elevated in a number a 
number of neurodegenerative disorders (Stone, 2001).
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That kynurenic acid was unable to block the effects of quinolinic acid could be due to 
the fact that the compound was inducing cell damage primarily via free radical 
generation, independent of glutamate receptors as has previously been suggested 
(Rios & Santamaria, 1991; Behan et ah, 1999).
<5.3.2. Ejfect o f CGS 21680 on cortical neuronal cultures.
So what is the role of the adenosine A ia receptor in modulation of neuronal viability? 
It is generally accepted in the literature that CGS 21680 is selective for A 2 A receptors 
at a concentration of 0.02 jiiM (Klotz, 1999; Muller, 2000). In the current study at 
this concentration, CGS 21680 was able to prevent NMDA induced cell death.
This is in agreement with the study of Feneira et al. (2001) who demonstrated that 
CGS 21680 was neuroprotective in cultures of avian retinal neurons and the report of 
Lee & Chao (2001). These latter authors revealed that CGS 21680 (0.001 pM) was 
able to rescue primary hippocampal neurons from withdrawal of growth factor 
induced apoptosis.
When the concentration of CGS 21680 was increased to 0.05 pM the compound 
apparently increases neuronal cell death. However when the concentration of this 
compound was increased to 0.5 pM and 5 pM there was a trend in that the compound 
was neuroprotective and at the highest dose used neuroprotection is observed. The 
adenosine A2 A receptor has a wide range of neuromodulatory effects which could be 
either neuroprotective or neurodetrimental. One of the latter effects is inhibition of 
neuroprotective adenosine A% receptors and glutamate release (Cunha, 2001), an 
action that would occur at a low concentration of CGS 21680. Thus it is likely that 
this inhibitory effect was occurring at 0.05 pM and was staiting to overcome the 
neuroprotective neuromodulatory effects of CGS 21680.
Although CGS 21680 is the prototypical A2 A selective agonist, at 0.5 pM and 
especially at 5 pM the compound can act as a direct agonist at adenosine Ai receptors 
(Muller, 2000; Klotz, 1999).
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Thus CGS 21680 was probably directly activating Ai receptors at the highest dose 
used in the project which would have overcome any inhibition of this receptor 
resulting from A2 A receptor activity. Activation of the adenosine Ai receptor is 
neuroprotective in cell culture (Mendonca et ah, 2000) and so this effect would 
explain the neuroprotection observed at this highest dose of CGS 21680.
6J.3. Ejfect o fZM 241385 on cortical neuronal cultures.
In vivo data have shown that adenosine A2 A receptor antagonists are neuroprotective 
and that this is a centrally mediated effect (Jones et ah, 1998a; Behan & Stone, 2002).
0.05 pM is a concentration at which ZM 241385 is selective for adenosine A2 A 
receptors (Moreau & Huber, 1999). At this concentration, the agent protected against '
100 pM NMDA-induced cell damage but not against that induced by 30 pM of the 
excitotoxin. Why this was the case is suggested below.
During the pathology of ischaemia and excitotoxicity, there is a release of adenosine 
(Latini & Pedata, 2001). The release of the “retaliatory metabolite” may be either 
neuroprotective or neurodetrimental depending on the degree of ischaemia and cell 
damage. Thus, when cell damage is mild the extracellular concentration (1-10 pM) 
of adenosine would only be sufficient to activate adenosine Ai receptors, an effect 
which would be protective. However, when cell damage is more severe and the 
concentration of adenosine rises to above about 20 pM it would activate A2 A 
receptors, an action which would inhibit Ai receptor activation and then increase 
glutamate release. This effect could be neurodetrimental.
NMDA is known to induce release of adenosine from the cortex in vitro (see Latini &
Pedata, 2001). Furthermore, Schousboe et al. (1989) showed that adenosine release 
can be induced by NMDA in cerebellar granule cell cultures. Therefore, it is likely 
that this same NMDA induced release of adenosine would occur in cortical neurons in 
vitro. Thus, it is appealing to speculate that the reason ZM 241385 was able to 
protect against damage induced by the highest concentration of NMDA is because it 
was releasing the A2 A receptor mediated inhibition of Ai receptors, so allowing 
adenosine to exert neuroprotection via this receptor.
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It would also be antagonising any Aia receptor mediated glutamate release induced by 
a pathological extracellular accumulation of the purine evoked by NMDA.
However, it should be noted that there is a possibility that the effects of ZM 241385 
could be due to effects of this compound on receptor number. For example, Varani 
& colleagues (1999, 2000) reported that chronic blockade of adenosine A2 A receptors 
caused an upregulation of the receptor and sensitization of the responses to 2-hexenyl- 
5-N-ethyl carboxamido adenosine (HE-NECA). It is possible that this same receptor 
adaptation occurred in the neuronal cultures in the present project as the cells were 
exposed to ZM 241385 for 72 hr which could be long enough for an upregulation of 
the adenosine A2 A receptor to occur so that the antagonist induces the same response 
as the agonist. Therefore, although it is less likely than the hypothesis detailed 
above, it cannot be excluded that ZM 241385 was upregulating adenosine A2 A 
receptors and allowing protection by endogenous adenosine through these upregulated 
receptors.
6.4. Discussion of the signal transduction mechanism by which the adenosine À2a 
receptor elicits neuroprotection.
Although further experiments would be necessary to elucidate the signal transduction 
mechanisms responsible for the neuroprotection observed with CGS 21680, it is not 
unreasonable to speculate on this now. There are a wide range of neuromodulatory 
mechanisms whereby CGS 21680 could have exerted this neuroprotection (see Table 
1 Introduction). However, the two most likely mechanisms aie transactivation of 
neurotrophin receptors via Akt activation (Lee & Chao, 2001) and inhibition of 
NMDA conductance via CamKll activation (Wirkner et al., 2000) as these effects 
have been demonstrated in primary neuronal culture.
CGS 21680 was able to reduce cell death induced by 10 pM NMDA but the NMDA- 
selective antagonist, AP5 was unable to reduce cell damage induced by this 
concentration of the excitotoxin.
ïFulthennore, COS 21680 showed an apparent tendency to be more effective in
■ :
reducing cell damage elicited by 30 pM NMD A than AP5. Also, ZM 241385 had no 
effect on cell damage induced by these concentrations of NMD A. It has been shown 
that adenosine A za receptor blockade enhances NMDA calcium conductances in 
striatal neuronal cultures (Popoli et al., 2002). Therefore, had ZM 241385 been 
blocking any adenosine A%A receptor mediated effects on NMDA channel 
conductance, one would have expected ZM 241385 to increase cell damage induced 
by NMDA to above control levels. This did not occur. Thus, it is tentatively 
suggested that CGS 21680 was transactivating neurotrophin receptors in this A za 
receptor mediated- protective effect IFigure 22).
6.5. Discussion of the mechanism of cell death induced hy glutamate receptor 
ligands.
The mechanism of cell death elicited by both quinolinic acid and NMDA appeared to 
be necrotic as assessed by trypan blue uptake. However, it is now evident that the 
distinction between apoptosis and necrosis in excitotoxicity on morphological 
grounds is becoming increasingly bluired. Thus, it cannot be excluded that there was 
an apoptotic component to excitotoxicity in the present study. Indeed, it has been 
shown that NMDA (Tenneti et al., 1998; Tenneti & Lipton, 2000) and quinolinic acid 
(Qin et al., 2000) can induce caspase-3 dependent neuronal cell death. Thus it is 
possible that this form of cell death was occurring as well as necrosis.
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Figure 22. Summary of the mechanisms whereby adenosine and 
adenosine A2A receptor ligands could modulate cell damage during an 
ischemic insult. When ischemia and cell damage is mild, the concentration 
of extracellular adenosine will only be between 1 and 10 (Latini & Pedata, 
2001) and so the purine will exert neuroprotection. The main mechanisms 
whereby this would be achieved would be 1) attenuation of glutamate release 
(via presynaptic inhibitory Ai receptors), 2) indirect modulation of glutamate 
receptors (both Ai and A2A mediated) and 3) transactivation of TrkB 
neurotrophin receptors. Adenosine A2A receptor agonists would synergise in 
this latter action.
However, during a heavier ischaemic insult, cell damage will be more severe 
and the concentration of adenosine could rise to 20 pM or more, a situation in 
which activation of A2A receptors would increase the release of glutamate (4). 
The cell damage caused by release of the excitatory amino acid would 
overcome the neuroprotective modulatory effects of Ai and A2A receptor 
activation. In this scenario, adenosine A2A receptor antagonists would be 
beneficial.
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1. Discussion of the effects of glutamate and adenosine receptor ligands on bone
cell cultures.
7.1. Differentiation of MC3T3-E1 cells.
Cells maintained in medium with the osteogenic supplements ascorbic acid and p- 
glycerol phosphate showed a 2-fold enhanced expression of alkaline phosphatase 
compared to cells maintained in medium without these supplements, an obervation in 
agreement with the literature (Quarles et ah, 1992). As alkaline phosphatase 
expression is commonly used as a marker of osteoblast differentiation, it is cleai' that 
the MC3T3-E1 cultures used were capable of expressing the osteoblast phenotype and 
therefore represent a good in vitro model for examining the effects of potential 
osteogenic agents.
7.2, Effect of NMDA on MC3T3-E1 cell development.
7.2. i. Ejfect o f NMDA on MC3T3-E1 cell proliferation.
In the present study, NMDA enhanced MC3T3-E1 cell proliferation. There are 
conflicting reports on the role of glutamate in bone cell viability. Gray and 
colleagues (2001) showed that NMDA did not have an effect on bone formation in 
primary rat osteoblasts, whereas others have shown that glutamate acts as a trophic 
factor in bone cell development as assessed by markers of differentiation and 
reduction of apoptosis (Taylor & Skeny, 2001; Genever & Skerry, 2001). In 
agreement with the latter observations, the cuiTent data suggests strongly that the 
transmitter acts as a mitogen on bone cells via the NMDA receptor.
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7.2,2. Ejfect o f N-methyl-D-aspartate on MC3T3-E1 cell differentiation.
NMDA increased alkaline phosphatase expression in MC3T3-E1 cells, an effect 
which the NMDA selective antagonist AP5 trended to reduce. Although Genever & 
Skerry (2001) reported that glutamate increased MC3T3-E1 cell differentiation, the 
present data are the first to demonstrate that the transmitter mediates some of this 
trophic effect via the NMDA receptor. It is believed that this is the first study to report 
that this glutamate receptor subtype mediates the trophic effects of the transmitter on 
bone cells. It is known that glutamate acting on NMDA receptors is essential as a 
neurotrophic factor during early development of the CNS (Burgoyne et al., 1993) and 
thus, it seems that this property of the transmitter extends to bone cells.
7,3. Effect of QA on MC3T3-E1 cell development.
7.3.1. Ejfect o f QA on MC3T3-E1 cell proliferation.
Quinolinic acid was also mitogenic for MC3T3-E1 cells. Again, as far as it is known 
this is the first study to demonstrate that the compound has a mitogenic effect on bone 
cells. However, it is not the first observation to demonstrate a role for the kynurenine 
in cell proliferation. Rzeski and colleagues (2001) showed that tumour cells express 
glutamate receptors and the kynurenine pathway is expressed in local immune cells 
during tumour growth (Moffett et al., 1997). The same occurs in bone cells (Stone & 
Darlington, 2002). Thus, it is possible that kynurenine pathway activation during 
bone remodelling disorders could influence proliferation in this tissue.
7.3.2. Ejfect ofQA on MC3T3-E1 cell differentiation.
As with NMDA, quinolinic acid increased alkaline phosphatase in MC3T3-E1 cells, 
an effect which AP5 showed an apparent tendency to reduce. However, the top 
concentration of QA showed a tendency to decrease cell differentiation. As far as it 
is known, this is the first report demonstrating a role of the kynurenine in bone cell 
differentiation.
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«The mechanisms of action for these trophic effects of QA and NMDA remain to be 
determined. However, it has been shown that QA can induce NGF activity in 
astroglia (Dong-Ruyl et al., 1997) and this neurotrophin induces differentiation of 
MC3T3-E1 cells (Yada et ah, 1994) so perhaps this same growth factor induction by 
the kynurenine is occurring in osteoblasts. Also, it is known that in the CNS, there is 
a close synergistic relationship between glutamate and neurotrophic factors 
(Lessmann, 1998) so perhaps this property extends to non-neuronal cells.
Interestingly, it has been shown that 4-hydroxynonenal, one of the major products of 
lipid peroxidation can have opposing effects on cell proliferation and differentiation 
(Parola et al., 1999). Furthermore, at 3000 pM, quinolinic acid has been suggested to 
have a negative effect on lipid peroxidation in rat brain (Stipek et al., 1997). The |
present data show that at this concentration quinolinic acid was able to induce cell 
proliferation but tended to inhibit differentiation. The latter action at least was not 
mediated via the NMDA receptor as AP5 did not have any significant effect on it.
Thus, it is pleasing to hypothesise that byproducts of lipid peroxidation have a
negative effect on MC3T3-E1 cell proliferation but a positive effect on their ï
i-idifferentiation. Finally, the data also raises the tantalising question of whether the
kynurenine pathway itself (Stone, 1993; 2001) is actually active in bone cells.
5r
a7.4. Effect of adenosine A2A receptor ligands on MC3T3-E1 cell development.
7.4.1. Ejfect o f adenosine A 2A receptor ligands on MC3T3-E1 cell proliferation.
CGS 21680 had a mitogenic effect on MC3T3-E1 cells. This is not the first evidence 
for the adenosine A2A receptor inducing cell proliferation. Sexl et al. (1995) showed 
that the adenosine A%A receptor could induce capillary outgrowth and endothelial cell 
proliferation. Furthermore it has been demonstrated that the adenosine A2 A receptor 
can induce proliferation in thyroid cells (Ledent et al., 1998). Also, the receptor has 
been suggested to play a role in trout male germ cell proliferation (Loir, 2001).
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ZM 241385 was also proliferative for MC3T3-E1 cells. That the response is not 
attenuated by the presence of ZM 241385 but is in fact enhanced by it is most likely 
due to an effect on receptor upregulation (Varani, 1999; 2000) as the cells were 
exposed to the agents for 72 hr. As ZM 241385 alone was able to cause a response, 
this suggests that there is a basal release of adenosine which mediates proliferation. %
However, it should be noted that Klinger and colleagues (2002) demonstrated that the
■i'adenosine A2 A receptor can show constitutive activation of MAP kinases so it is I
I .possible that the upregulated receptor was inducing proliferation in the absence of the 
purine.
That there is adenosine signalling in bone cells has been shown previously. Shimegi 
(1996; 1998) reported that adenosine could induce proliferation in these cells. It was 
suggested that adenosine mediated some of this effect via Ai receptors as it was 
sensitive to cyclopentylxanthine and pertussis toxin but some of the effect was 
insensitive to these agents. The present data are the first to reveal using adenosine 
A2 A receptor ligands that this adenosine receptor subtype is capable of inducing 
proliferation of MC3T3-E1 cell, although the data would have to be confiimed by cell 
counts. However, it should be mentioned there is a possibility that in these cells, 
there is a site recognised by CGS 21680 that is not the “classical” A2 A receptor as
reported for the CNS neurones (Lindstrom et al., 1996). Nevertheless, the present I'-'idata strongly supports the existence of functional adenosine A2 A receptors in this cell 
line.
7.4.2. Ejfect o f adenosine A 2A receptor ligands on MC3T3-E1 cell differentiation,
CGS 21680 showed a trend of increasing alkaline phosphatase expression in MC3T3- 
E1 cells which ZM 241385 trended to reduce. Although as mentioned above the 
adenosine A2 A receptor is known to have a proliferative effect on a number of cell 
types. As far as it is known, this is the first data to report that this receptor has an 
additional trophic role and is capable of enhancing cell differentiation.
104
The signal transduction pathway that underlies this trophic effect of the A2 A receptor 
ligands remains to be determined. It is established that in the CNS, the adenosine 
A2 A receptor enhances glutamate release (Marchi et al., 2002). Skerry and Genever 
(2001) reported that glutamate induces alkaline phosphatase expression in osteoblasts 
so the obvious mechanism whereby the receptor can induce differentiation of 
MC3T3-E1 cells is by increasing glutamate release.
However, it is known that the adenosine A2 A receptor has a close synergistic 
relationship with growth factors, especially NGF (Arslan et al., 1997; Arslan & 
Fredholm, 2000; Lee et ah, 2002) and this neurotrophin can induce differentiation of 
MC3T3-E1 cells (Yada et al., 1994). In addition, as just mentioned, it is apparent 
that the adenosine A2 A receptor can activate MAP kinases so it is possible that the 
proliferation observed was mediated via this pathway. Thus, it is possible that the 
adenosine A2 A receptor was enhancing differentiation of MC3T3-E1 cells by this 
mechanism or a combination of these mechanisms.
7.5. Effect of nitrosative and oxidative stress on MC3T3-E1 cell viability,
7.5. i. Ejfect o f nitrosative stress on MC3T3-E1 cell viability.
As neither of the glutamatergic ligands caused excitotoxicity in MC3T3-E1 cells 
alone, it was decided to see if they were able to cause cell damage under conditions of 
nitrosative and oxidative stress as has been demonstrated recently in the CNS (Behan 
& Stone, 2002). In the present study, the nitric oxide donor, S-nitroso-N- 
acetylpenicillamine (SNAP) failed to induce death of MC3T3-E1 cells contrary to the 
report of Damoulis & Hauschka (1997). However, these authors did not use 
ascorbate supplemented media in their study whereas in the cuiTent study, ascorbate 
and |3-glycerolphosphate was used to enhance cell differentiation. Ascorbate is a 
natural antioxidant (see e.g. Hailiwell, 1999) and it is possible that the presence of it 
in the media was preventing SNAP from causing cell damage to MC3T3-E1 cells.
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7.5.2. Ejfect o f oxidative stress on MC3T3-E1 cell viability.
However, cell damage using hydrogen peroxide (H2 O2 ), a well established donor of 
oxidative stress was obtained in the current study, observations in agreement with the 
literature (Mody et al., 2001). That H2 O2  was able to induce cell injury whereas 
SNAP was not suggests that the formation of reactive oxygen species by the H 2 O2 
was able to overwhelm the antioxidant effects of ascorbate and explain the 
insensitivity of MC3T3-E1 cells to low concentrations of H2 O2 .
In support of this idea, Chiarugi et al. (2001) showed that ascorbate cannot protect 
neuronal cells from all forms of oxidative injury so it is possible this lack of a 
protective effect of ascorbate could extend to bone cells as well. Neither NMDA or 
quinolinic acid were able to modulate hydrogen peroxide induced cell damage. 
However, it is interesting to note that 10 pM H2 O2 non-significantly increased cell 
proliferation. Furthermore, 100 pM H2 O2  did not induce statistically significant cell 
death but was able to reduce the proliferative effect of the A2 A ligands to near control 
levels. These observations are in agreement with the literature that low 
concentrations of hydrogen peroxide have a stimulatory effect on cell growth whereas 
high concentrations (>100 pM) tend to induce cell death (Burdon, 1995).
It has been reported that the adenosine A2 A receptor has an antioxidant effect in 
certain cell types. Lee & Emala (2002) demonstrated that the receptor attenuated 
hydrogen peroxide-induced injury in proximal tubular cells using HK-2 cells. 
Furthermore, Fredholm et al. (1996) showed that the receptor mediated the inhibitory 
effect of adenosine on formyl-Met-Leu-Phe-stimulated respiratory burst in neutrophil 
leucocytes. However, as CGS 21680 was unable to affect cell damage induced by 
H 2 O2  in this study, these results suggest that this antioxidant effect does not extend to 
bone cells.
106
7.6. Effect of serum withdrawal on caspase-3 expression in MC3T3-E1 cells.
Serum withdrawal increased the amount of apoptosis in MC3T3-E1 cells as assessed 
by immunostaining for caspase-3. Previous studies with this cell line have shown 
that caspase-3 expression is induced by staurosporine (Chae et al., 2000) and hypoxia 
(Chae et al., 2001). Furthermore, Jilka and colleagues (1998) demonstrated that 
serum withdrawal from MC3T3-E1 cells increased apoptosis as assessed by teiTninal 
deoxynucleotidyl transferase-mediated dUTP-nick end labeling. However, the 
present data is the first to demonstrate that removal of growth factor support induces 
apoptosis as assessed by caspase-3 expression in this cell line. Neither adenosine Ai 
or A2 A receptor ligands, nor quinolinic acid had an effect on apoptosis. This could 
either be because the receptor is not yet expressed at this early stage of treatment in 
vitro or simply that adenosine receptors do not have an anti-apoptotic effect in these 
cells.
However, glutamate acts as a trophic factor in osteoblasts (Genever & SkeiTy, 2001) 
and expression of the phenotype for glutamate is differentiation dependent (Bhangu et 
a l, 2001). Adenosine A2 A receptors increase glutamate release in the CNS (Cunha,
2001). As discussed below, A2 A receptors appear to have a mitogenic effect on 
MC3T3-E1 cells and so it would be surprising if they did not have additional trophic I
actions. Therefore, to confirm that adenosine receptors and quinolinic acid do not 
have a modulatory effect on caspase-3 dependent apoptosis in MC3T3-E1 cells it 
would be interesting in the future to treat them at a later stage in vitro when they are 
starting to differentiate.
107
8. General discussion.
8.1. Discussion of a cell line vs. the use of a primary culture for examining the 
effects of glutamate on cell development.
It was mentioned in the Introduction what the general advantages and disadvantages 
of primary cultures vs. cell lines for the assessment of neurotoxicity were. However, 
the merits and pitfalls of each based upon experience in their use is now discussed. 
On the whole, it was felt that the advantages of the cell line over the primary culture 
system were numerous. The former system on the whole was easier to set up and 
maintain and the cells in general seemed a lot more robust. Furthermore, they turned 
out to be more economical than the primary culture system as they did not require the 
use of an expensive substrate (laminin) and were easier to set up in 96 well plates than 
the neuronal cultures. Furthennore, the setting up of a breeding colony for the 
establishment of primary cultures is an expensive operation and this is obviously not 
necessary when a cell line is used. Furthermore, less time, effort and expense is 
needed for the characterization of the cell line as regards cell type is required as 
previous studies have revealed that the cell line consists of a homogenous cell 
population. (Quarles et al., 1992). Therefore, it was only necessary to ensure they 
differentiated in accordance with the literature by assaying for alkaline phosphatase.
8.2. Osteoblasts appear not to be vulnerable to excitotoxicity.
In the present study, MC3T3-E1 cells did not succumb to excitotoxicity as did 
primary neuronal cultures. NMDA and quinolinic acid had a mitogenic effect on 
MC3T3-E1 cells. However, as mentioned earlier, it is generally appreciated that a 
primary cell culture more closely represents the situation in vivo than a cell line. 
Therefore there is always the possibility that due to the homogeneity of the cells in the 
MC3T3-E1 system, the cellular interactions would be restricted and the cells are not 
exposed to the same complicated network of messages typical of neuronal circuits that 
is present in primary neuronal cultures.
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However, this is unlikely to be the case as to why MC3T3-E1 cells did not succumb 
to excitotoxicity as Skeixy & Taylor (2001) reported that primary rat osteoblasts, 
SaoS-2 cells and MG 63 cells did not exhibit cell death in response to mM quantities 
of AMPA, glutamate or NMDA. Furthermore, the expression and developmental 
regulation of glutamate receptors and NMDA receptor subunits in the latter cell line 
and in primary osteoblasts occurs as it does in the CNS (Itzstein et al., 2001). Also, 
NMDA receptors in bone cells have the same electrophysiological chai’acteristics as 
their neuronal counterparts (Skerry & Taylor, 2001; Gu et ai., 2002).
However, glutamate is known to be essential as a neurotrophic factor during CNS 
development (Burgoyne et al., 1993). In cerebellar granule cell culture, Hunt & Patel 
(1990) showed that quinolinic acid at concentrations as high as 2 mM promoted the 
differentiation of these neurons when they were treated at an early stage. Yet 
concentrations as low as 100 pM can be toxic to these cells if exposed to the agent at 
7 days in vitro (Hossain et al., 2002). The same is true of NMDA, 30 pM of the 
compound can have a trophic action on these cells at an early stage of development 
e.g. within hrs of plating (Pearce et ai., 1987) but this concentration can also be 
neurotoxic to the cells when exposed after 8 days in vitro (Hossain et al., 2002). 
Thus, glutamate can be a neurotrophic factor but it can also be an excitotoxin 
depending on the stage of development of the cells.
Expression of the glutamate phenotype is differentiation dependent in MC3T3-E1 
cells (Genever & Skerry, 2001) and appearance of alkaline phosphatase is not evident 
until the onset of growth arrest until about day 9 in culture (Quarles et al., 1992). 
The expression of alkaline phosphatase in the cultures used in the project was in 
agreement with this. The present data showed that NMDA and quinolinic acid 
appeared to be acting as trophic factors in MC3T3-E1 cells when the cells were 
treated as late as 11 DIV. However, it is certainly possible that this is still an age at 
which glutamate is a trophic factor in bone cell development. Thus, it is possible that 
had the cells been treated at a later stage than this they would have been vulnerable to 
excitotoxicity.
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There is also the possibility that the incubation period used for the excitotoxins 
simply was not long enough to induce cell death as it was observed that a 24 hr 
exposure to NMDA and quinolinic acid induced proliferation. However, after a 72 hr 
exposure to the compounds this mitogenic effect was not evident. Thus, it is possible 
that had the cells been incubated with the agents longer, excitotoxicity might have 
occuned. However, it is possible osteoblasts cannot succumb to excitotoxicity at all. 
Osteoblastic glutamate release is negatively regulated by depolarization and voltage- 
dependent calcium entry (Genever & Skerry, 2001) whereas central glutamate release 
is positively coupled to voltage dependent entry of Ca^ "^ . (Nizhikawa, 2001). Thus in 
the CNS, NMDA and QA (Tavares et al., 2002) acting on autoreceptors contributes to 
the pathological accumulation of glutamate in the extracellular space as does 
depolarization induced reversal of the glutamate transporter. However, it is unlikely 
that the same mechanisms come into play when osteoblasts are exposed to these 
agents due to this inate difference in voltage-regulated calcium dependent glutamate 
release.
8.3. Further work.
First, it should be stressed that it would be necessai'y to repeat the experiments for 
each data point in triplicate over 3 different culture preparations for the neuronal data 
and over 3 different subcultures for the bone cell data in order to confirm that the data 
is indeed truly statistically significant.
Further work could be performed examining the neuroprotective mechanism of action 
of the A2 a receptor ligands. There is evidence that CGS 21680 binds to two different 
sites in rat brain (Lindstrom et al., 1996). Therefore, initially, it would be interesting 
to characterise the cells as regards the existence of the “classical” A2 A receptor in 
culture using ligand binding, Western Blotting, RT-PCR and immunocytochemistry. 
Also, it would be necessary to ascertain whether the A2 A receptor mediated protective 
effect is mediated via the “classical” receptor by seeing if chemically dissimilar 
antagonists attenuated the effect of CGS 21680 and pA2 values for the antagonists 
calculated. In addition, unfortunately, the project only assessed the effects of chronic 
treatment with the A2 A ligands on excitotoxicity.
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It is known that adenosine receptors can experience “effect inversion” (Jacobson et 
a l, 1996) and in the clinic and potential therapeutic situations, the compounds could
be used either acutely or chronically. Thus it would be necessai'y to assess what 
effects different treatment times have on the neuroprotective effects of the A2 A 
ligands. Furthermore, it would be very exciting to elucidate the signal transduction 
mechanisms responsible for the A2 A-receptor mediated neuroprotection. These are 
likely to be inhibition of NMDA channel function and transactivation of neurotrophin 
receptors.
It is possible that with neuronal cultures some of the protection exhibited by the 
adenosine A2 A receptor could be due to indirect effects on glial cell function, it would 
be needed to explore this possibility in order to gain a full understanding of the 
neuroprotective modulatory action these compounds show by using pure glial 
cultures.
With regard to the work on osteoblasts, it would be interesting to see if osteoblasts 
succumb to excitotoxicity when exposed to higher concentrations of glutamate 
receptor ligands than were used in the project. Also, it would be useful to see, 
using the aforementioned techniques if glutamate receptors do show the same 
developmental expression in MC3T3-E1 cells in vitro as they do in cultured central 
neurons and if they need to be treated at a certain stage to succumb to excitotoxicity.
In addition, it would be interesting to fully elucidate the role of adenosine A2 A 
receptors in osteoblastic function and pathology. The present data strongly suggest 
the existence of functional A2 A receptors on MC3T3-E1 cells in vitro. However the 
existence of the receptor should be confirmed using the molecular biological and 
immunocytochemical techniques mentioned above and if so, it would be fruitful to 
use this cell line to see if the adenosine A2 A receptor has the capacity to protect 
against excitotoxicity if this occurs in bone cells.
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8.4. Conclusions.
To summarize this project has indicated that the adenosine A2 A receptor is 
neuroprotective against a mild excitotoxic insult but is neurodetrimental when cell 
damage becomes more severe. The choice of which ligand to use in the whole 
animal and the clinic could depend upon the degree of excitotoxicity and cell damage.
The use of a low dose of an adenosine A2 A receptor agonist which did not induce any ^
haemodynamic changes might be useful in the treatment of chronic neurodegenerative 
disorders where cell death occurs primarily via an apoptotic mechanism e.g 
schizophrenia. ;
However, when excitotoxicity and cell damage are more pronounced as occurs 
during ischaemia, the use of an adenosine A2 A receptor antagonist would be the better
■ tchoice. There is always the risk that an antagonist might block beneficial A%A %
receptor-mediated effects on blood pressure and on platelet aggregation (Jones et al.,
1998). Although encouraging data from Monopoli and colleagues (1998a) have 
revealed that after i.p. administration in rats, SCH 58261 did not induce hemodynamic 
changes up to a dose of 0.1 mg/kg but increased blood pressure and heart rate starting 
from a dose of 1 mg/kg. Therefore, when used at the “con-ect dose”, an adenosine 
A2 A receptor antagonist would exert protection via blocking central A 2A receptor 
evoked neurodetrimental effects without compromising beneficial A2 A receptor 
mediated peripheral effects. However, more studies in the whole animal are needed #
to clarify this.
With regard to the work on bone cells, this project has revealed that the NMDA 
receptor and the A2 A receptor have a trophic effect on osteoblasts in vitro.
Furthermore, it has supported the idea that MC3T3-E1 cells are a good in vitro system 
for examining the role of adenosine A2 A receptors in osteogenesis. Adenosine A2 A 
receptors and the kynurenine pathway could offer a therapeutic target in the treatment 
of bone remodelling disorders marked by a loss of osteoblastic function e.g. 
osteoporosis and periodontal disease.
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